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Osteoporosis is caused by an imbalance between bone formation and bone 
resorption that results in low bone mass and deteriorated bone microstructure 
and finally elevates the risk of low-trauma fracture. For developing new 
therapies for managing osteoporosis, this study compromised 3 stages as 
follows: 1, the bone formation efficacy of recombinant human bone 
morphogenetic protein 2 (rhBMP-2) was investigated since bone substitute is 
necessary for osteoporosis patients; 2, the efficacy of currently available 
medications was analyzed via meta-analysis; 3, the impact brought by the 




results were as follow. In the first part, we compared the osteoinductivity of 
Escherichia coli rhBMP-2 (ErhBMP-2) with Chinese hamster ovary cell-
derived rhBMP-2 (CrhBMP-2) with human mesenchymal stem cells and rat 
calvarial defect. In the second part, we systematically reviewed the effect of 
current osteoporosis medications on preventing secondary osteoporotic 
vertebral and non-vertebral fractures from randomized controlled studies and 
synthesized their result via meta-analysis. In the third part, we compared the 
transcription level of DRG2 in osteoporosis and non-osteoporosis subjects, and 
furtherly fabricated Drg2 knockout mice and analyzed the difference in bone 
phenotype of wild type and Drg2 knockout mice. At the end of this part, we 
investigated the possible mechanisms and signals Drg2 involved in osteoblastic 
differentiation. The results from the first part showed ErhBMP-2 could have 
comparable osteoinductivity with Chinese hamster ovary cell-derived BMP-2 
while using the demineralized bone matrix as the carrier. In the second part, we 
found the medications could have a consistent effect on osteoporosis patients, 
regardless of their fracture history. And in the third part, we found osteoporosis 
patients had higher expression level of Drg2 and knocking out of Drg2 in mice 
significantly improved bone mass and mineral density even if mice were 
ovariectomized. The bone marrow-derived macrophage in Drg2 knockout mice 
showed lower osteoclastogenesis while the bone marrow mesenchymal stem 
cell concurrently showed higher osteoblastogenesis than wild type mice. 
Furtherly, inhibition of Drg2 expression in mouse MC3T3-E1 cells elevated its 
osteogenicity via canonical and non-canonical BMP pathway. In summary, we 




agent for osteoporosis fracture; currently available medications could have a 
significant effect on preventing secondary osteoporotic fracture; and Drg2 as 
an important regulator in bone remodeling, which suggested Drg2 inhibitor 
could be a potential anabolic for treating osteoporosis. 
Keywords: bone morphogenetic protein 2; developmentally regulated 
GTP-binding protein 2; osteoporosis; bone remodeling; osteogenesis; 
osteoblast; osteoclast; animal experiment;  
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With the increase of the public health burden of osteoporosis, the 
considerations of managing the debilitating condition increases. Osteoporosis 
fracture presents a unique clinical challenge because the osteoporotic bone is 
less likely to heal on its own and require surgery to repair the fracture.[1] Since 
obtaining optimal union in osteoporotic bone is of utmost importance, treating 
surgeons must be aware of the treatment algorithms to enhance clinical 
outcomes.[2] Because of the decreased expression of bone morphogenetic 
proteins (BMPs), an essential growth factor in fracture healing made the BMPs 
attractive for promoting bone healing in osteoporotic fracture patients.[3] 
Two kinds recombinant human bone morphogenetic protein-2 were available 
currently, one is Chinese hamster ovary-derived rhBMP-2 (CrhBMP-2) and the 
other one is Escherichia coli (ErhBMP-2). ErhBMP-2 has larger yield and 
lower cost, but slightly lower osteoinductivity.[4-8] Also, the newly formed 
bone induced by ErhBMP-2 had more cyst-like structure and fatty tissue in the 
center, which was related to its expanding in the defect site.[6, 9] Therefore, an 
optimal delivery system was critical to optimize the efficacy of ErhBMP-2. 
Among the delivery systems,[10] demineralized bone matrix (DBM) was both 
osteoconductive and osteoinductive and has been as a scaffold for bone 
regeneration.[11-14] However, the effectiveness of DBM was inferior to 




variety.[12, 15, 16] Therefore, using DBM as a delivery system for rhBMP-2, 
which could provide a controlled release of the growth factor, could be 
appropriate to promote bone regeneration. Since the efficacy of DBM as a 
carrier of ErhBMP-2 was less investigated, we compared the osteoinductivity 
of ErhBMP-2 and CrhBMP-2 while both were loaded by it. 
Other than promoting bone formation in the fusion region, controlling the 
osteoporosis itself was also an important part in managing osteoporotic 
fracture.[2] As a metabolic bone disease, osteoporosis increases the risk of low-
trauma fracture in the wrist, hip, femur, and spine that leads to 
hospitalization.[17] Besides the pain and disability brought by the osteoporotic 
fracture, the bedridden after fracture also accompanies with complications like 
pressure ulcer, and deep vein thrombosis that could be life threating in elderly 
patients.[18, 19] Osteoporotic vertebral compression fracture (OVCF) is one of 
the most common fragile fractures, with a prevalence of 30% to 50% in people 
over 50 years of age.[20] It causes severe pain and disability, raises the risk of 
secondary fracture more than 4-fold [21, 22], and increases the risk of mortality 
[23]. Therefore, secondary prevention of OVCF was critical and should be 
emphasized to improve patients’ quality of life. However, though the primary 
prevention efficacy of medications has been well summarized [24-29], only one 
systematic review targeted on their secondary prevention effects.[30]  
Various medications, such as bisphosphonate, estrogen, receptor activator of 
nuclear factor kappa-B ligand (RANKL) inhibitor, and teriparatide have been 




mechanisms into antiresorptive and anabolic agents. The antiresorptive agents, 
like bisphosphonate and RANKL inhibitor, increase bone mass via suppressing 
bone resorption, but it cannot repair the bone structure that was already 
damaged.[31] Also, the medications have been shown to decrease the risk of 
secondary osteoporotic fracture, but the evidence in preventing both primary 
and secondary fracture was not as strong.[17] The anabolic agent, teriparatide, 
elevates both bone formation and resorption and therefore, increases bone 
mineral density (BMD) and reduces fracture risk in the vertebra and non-
vertebra fracture. But it has not been reported to reduce fracture risk of hip and 
could cause side effects such as nausea, headache, and hypercalcemia.[32] Also, 
the previous study more focused on the primary prevention of osteoporotic 
fracture.[24-26, 29, 33, 34] The efficacy of the medications therapies on 
preventing the secondary fracture still need to be investigated.  
Recently, a medication named romosozumab, a sclerostin inhibitor has been 
found to be both anti-resorptive and anabolic effects and presented a significant 
effect on treating osteoporosis.[35, 36] The medication indicated a potential of 
the medications possess both anti-resorptive and anabolic characters for 
reducing fracture risk, shorten rehabilitation time and reduce disability caused 
by the fracture.[37-39] 
Developmentally regulated GTP binding protein 2 (DRG2), a member of small 
G protein family, increases the activity of osteoclast (OC) and also regulates the 
activity of mesenchymal stem cells, which indicated a potential role of DRG2 




reported the effect of Drg2 on osteoblastic differentiation. Therefore, we 
compared the transcription level of DRG2 in mesenchymal stem cells of 
osteoporosis and non-osteoporosis subjects. Furtherly, we fabricated the Drg2 
knockout (KO) mice, investigated the effect of Drg2 on osteoclastic and 
osteoblastic differentiation and compared the BMD and bone architecture 
between wild type (WT) and KO mice under both biological and 
ovariectomized condition. In the end, we investigated the possible mechanisms 
of Drg2 regulating osteoblastic differentiation.  
Therefore, this article was composed of three part: in the first part, we 
compared the effect of ErhBMP-2 with CrhBMP-2 in bone healing inducing 
bone formation. In the second part, we systematically reviewed the effect of 
current osteoporosis medications on preventing secondary osteoporotic 
vertebral and non-vertebral fracture. And in the third part, we investigated the 






Osteoinductive treatment of human mesenchymal stem 
cells 
Human mesenchymal stem cells (hMSCs) (Lonza, Walkersville, MD) were 
seeded in 100mm dishes with MSCBM kit (Lonza, USA) and were incubated 
in a humified, 5% CO2, 37 ºC environment. For osteoinduction, the cells were 
seeded in 24-well plates with a density of 1 × 105/well and were cultured in the 
same environment as previously mentioned. After the coverage ratio reached 
70%-80%, the cells were separated into basal medium group, osteoinduction 
medium group, ErhBMP-2 (Novosis, CG-bio) 10ng/ml, 50ng/ml, 100ng/ml, 
250ng/ml and 500 ng/ml groups, and CHO-BMP-2 (Rafugen, Cellumed) 
10ng/ml, 50ng/ml, 100ng/ml, 250ng/ml and 500 ng/ml groups. The 
osteoinduction medium was composed of 10-8M dexamethasone (Sigma, St, 
Louis, Mo, USA), 50µM ascorbic acid-2-phosphate (Sigma, St, Louis, Mo, 
USA), 10mM β-glycerophosphate (Sigma, St, Louis, Mo, USA) low glucose 
DMEM and 10% fetal bovine serum, and the medium was changed every 3 
days. 
ALP staining and and ALP activity assay 
For ALP staining, fast blue RR salt was dissolved in distilled water and 




of 1:24. Cells were washed twice with DPBS. The fast blue RR salt/Naphthol 
AS-MX phosphate alkaline solution was then added followed by incubation at 
room temperature for 5 minutes. Staining was observed under optical 
microscopy (Leica). 
ALP activity was measured with a spectrophotometer. Cells were washed 
twice with DPBS and lysed with 0.2% Triton X-100. Cell lysates were assayed 
for ALP activity using p-nitrophenyl phosphate as a substrate. ALP activity was 
defined as the amount of p-nitrophenol released after incubation for 30 min at 
room temperature. The color change was measured spectrophotometrically at 
405 nm and the experiment was biologically repeated 3 times. 
Calcium staining and assay 
Wells were washed twice with DPBS, added with 40nM alizarin red solution 
and incubated at room temperature for 5 minutes. The mineral deposition was 
observed with optical microscopy (Leica). 
To quantify calcium formation with osteoblast differentiation, wells were 
washed with distilled water twice. Cells were lysed with 0.2 ml 0.5% HCl and 
2.5 μl of the sample was transferred into a 96-well plate. An equal volume of 
reagent A and reagent B from QuantiChrom calcium assay kit 
(BioAssaySystems, Hayward, CA, USA) was mixed together, and 200 μL of 
the mixture was added into each well. After incubating at room temperature for 
3 minutes, the optical density at 612 nm was measured with an ELISA reader. 





Expression levels of bone formation related genes were evaluated with real-
time PCR. 1 × 105 cells were cultured in 96 well dishes and induced for 7 days. 
Total RNA was isolated with RNeasy mini kit (Qiagen, USA), and was 
reversely transcribed with High Capacity cDNA Reverse Transcription Kit 
(Intron Biotechnology, Korea). After cDNA synthesis, real-time PCR 
(LightCycler® instrument, Roche) was performed with SYBR Green PCR 
Mastermix and ABI StepOnePlus real-time PCR system (Applied Biosystems, 
USA). The expression levels of ALP, Runx-2, OCN, BSP, OPN, and OCN was 
calculated as −2ΔΔCt.[41] 
RNAs were extracted using Qiagen RNeasy mini prep kit(Life Technology) 
and reverse transcribed into cDNA using Maxime™ RT PreMix kit(Intron 
technology). Real-time PCR was performed with SYBR Green and 
LightCycler® 480 Instrument ( Roche Life Science) real-time PCR system. The 
expression level was calculated as -2ΔΔCt, and the experiment was biologically 
repeated 3 times. The expression was corrected using GAPDH. [41] Primers 
used were listed in Table 4. 
Rat calvarial defect model 
The procedures that involved the use of animals were approved by the 
international animal care and use committee (SNUH IACUC No.13-0348). 
Eight-week-old male Sprague-Dawley rats (200–220 g, total N = 156) were 




specific-pathogen-free cage and were provided with abundant food and water. 
The experiments were performed after 1 week stabilization period and were 
randomly separated into ErhBMP-2 (Novosis, CGBio, Korea) 2.5 µg + DBM 
(Rafugen DBM gel, Cellmud, Korea) 0.05 ml group and CrhBMP-2 2.5 µg + 
DBM (Rafugen rhBMP-2 DBM gel, Cellumed, Korea) 0.05 ml group. 
Animals were anesthetized with an intraperitoneal injection of 20 mg/kg 
Zoletil and 10 mg/kg xylazine. The scalp was shaved and sterilized, and an 8 
mm calvarial defect was made. The composite from each group was implanted 
in the defect and the scalp was sutured.[42] All animals were injected 100 
mg/kg cefazolin and housed in the environment as previously described.[43] 
All animals were sacrificed with a CO2 chamber under deep anesthesia on their 
4th or 8th week after experiments. The implants were carefully harvested and 
were immediately fixed in 10% formalin for micro-CT evaluation and 
histological assessments. 
Micro-CT evaluation 
The rat calvaria samples were scanned with a Skyscan 1172 micro-CT scanner 
(Bruker, Belgium). The samples were scanned with the following setting: 11.93 
µm pixel size, 0.5 mm Al filter, 70 kV energy, 141 µA current, and 0.4˚ rotation 
step. The images were reconstructed analyzed with NRecon (Bruker, Belgium) 
and CT-An (Bruker, Belgium). The threshold values of newly-formed bone 
were referred to the native bone. Bone morphometric parameters, including 




bone pattern factor (Tb.Pf), structure model index (SMI), trabecular bone 
thickness (Tb.Th), trabecular number (Tb.N), trabecular separation (Tb.Sp), 
and degree of anisotropy (DA) were analyzed with an 8-mm diameter region of 
interest. 
The vertebra and femur samples from mice were scanned with the same 1172 
micro-CT scanner under the following setting: pixel size, 9.86 µm; 0.5 mm Al 
filter; energy, 59 kV; current, 167 µA; and rotation step, 0.4˚. Cross-sectional 
images were reconstructed using the NRecon package (Bruker, Belgium) and 
analyzed with a CT Analyzer software (CT-An, Bruker, Belgium). Threshold 
values of newly-formed bone were compared with those of native bone. 
Trabecular bone thickness (Tb.Th), bone volume (BV), and percentage bone 
volume (BV/TV) were calculated within 8-mm diameter regions of interest 
(ROI), generated based on the defect site. In spine samples, the ROI was set as 
an elliptic cylinder (1.08 mm * 0.8mm * 0.61mm) located in the caudal region 
of a vertebra. (Fig. Supplementary 1 a) In femur samples, the trabecular bone 
was selected with semi-auto selecting program in CTAn femur head, proximal 
femur neck, and proximal femur. (Fig. Supplementary 1 b-d) 
Hematoxylin and eosin staining 
The rat calvaria samples were fixed in 10% formalin, dehydrated in 80% to 
100% ethyl alcohol, infiltrated and embedded with Technovit 7200 resin 
(EXAKT, Germany). Then resin was solidified with a polymerization system 




ground to a 50 µm thick with an EXAKT grinding system (Germany). The 
ground slices were stained with hematoxylin and eosin, and the bone formation 
was observed with an optical microscope. 
The femur and vertebra of mice were fixed with formalin and were decalcified 
with 8% formic acid/8% HCl solution for 24 hours. After standard paraffin 
infiltration procedure,[44] samples were embedded in a paraffin block and 
sectioned at a thickness of 4 μm. After then, the slides were stained with 
hematoxylin and eosin and observed under an optic microscope. 
Search for studies 
Four major electronic databases (MEDLINE, EMBASE, CENTRAL, and 
Web of Science) were searched with a developed search strategy that consisted 
of keywords “controlled trials”, “osteoporotic fracture”, “bisphosphonate”, 
“parathyroid hormone”, “denosumab” “calcitonin”, “Raloxifene”, 
“Bazedoxifene” “hormone replacement”, etc., and others (Supplementary 
Material 1). The search spanned the period from June 2015 to December 2017, 
with weekly alerts of updated published trials. Reference lists from other 
reviews and studies were also checked for relevant articles. The references were 
managed with Endnote X7 (Clarivate Analytics). 
Selection of studies 
One author screened the titles and abstracts of studies and evaluated their 




osteoporosis. A subsequent full-text assessment was done by two reviewers. 
Randomized controlled trials (RCTs) published in English that investigated the 
efficacy of currently approved medications for patients with OVCF were 
included. The studies that included osteoporosis patients without distinguishing 
their fracture history were included if the data of the participants with prevalent 
fractures was adequately presented. Studies that recruited patients with 
traumatic vertebral fracture, secondary osteoporosis, or did not report results in 
dichotomous data (i.e., patient-years, etc.), were excluded. Post hoc analyzed 
RCTs were also included, with taking care of duplicated data input. 
Disagreements between reviewers were resolved by discussion or, if unresolved, 
by consultation with librarians from Seoul National University Medical Library 
and a statistic professor from Seoul Metropolitan Government Seoul National 
University Boramae Medical Center. 
Data extraction and risk of bias 
Basic characteristics of each study were extracted with a designed table that 
contains the number of participants, interventions, comparisons, and outcomes. 
The primary outcome of this study was the vertebral fracture ratio in the final 
visit, and the secondary outcomes were gastrointestinal (GI) complaints of 
bisphosphonates, discontinuation due to adverse events (AEs), and non-
vertebral fracture ratio. 
The risk of bias was measured with the tool recommended in updated 




rated for the main result (vertebral fracture). The loss ratio was acceptable for 
a middle- or long-term trial (observational period > 1 year), if that was not 
exceeded by 30%. The risk of other sources of bias was rated as low risk if the 
article stated both conflicts of interest and sponsor of the trial and no other 
serious risk of bias was reported. 
Data analysis and quality of evidence  
Relative risk (RR) and its 95% confidence intervals (CIs) were used to 
estimate the effect of interventions, with p-values < 0.05 considered significant. 
The overall effect size was calculated with a random effects model [45]. 
Heterogeneity between studies was identified and measured with p-value and 
I2 value from Chi-squared test, p-value < 0.1 was identified as significant, and 
I2 > 75% was identified as a considerable magnitude. In the studies that 
compared the effect of medications with placebo groups, the data from the 
medication groups were included in the intervention groups, and the data in the 
placebo groups were included in the control groups. In the studies with more 
than two arms, intervention groups were input into each subgroup and the data 
in the placebo groups were separated equally into control groups and were 
compared to their counterparts. Sensitivity analyses were used to explore the 
interference from a study by excluding it from syntheses and the impact from 
loss to follow-up population by compositing the missing events according to 





We evaluated five factors of the results to determine the quality of evidence, 
including study limitation, imprecision, indirectness, inconsistent and 
publication bias, followed the GRADE approach. The criteria for 
downregulating the level referred to the handbook of GRADE and guidelines 
from Cochrane Back and Neck Group.[45, 46] In the case that an outcome 
included one trial with no unclear or high risk of bias, the study limitation item 
was rated as not serious if its result remained same direction and significance 
with the pooled result. 
Extraction of mesenchymal stem cells from human 
Human ilium source mesenchymal stem cells were obtained during surgery 
for patients from the Seoul Metropolitan Government – Seoul National 
University Boramae Medical Center. All clinical procedures were approved by 
the Institutional Review Board of Seoul Metropolitan Government – Seoul 
National University Boramae Medical Center (IRB No. 06-2009-107). 
Informed consent was obtained from participants. 
Fabrication of DRG2 knock out mouse 
Drg2 KO founder mice were produced with C57BL/6N strain using 
CRISPR/Cas9 technique at Korea Research Institute of Bioscience and 
Biotechnology (KRIBB). For mutant lineage establishment, founder mouse 




Genomic typing and gender determination 
For genomic typing, 2-3mm tail tissue was dissected under gaseous anesthesia. 
Tail tissue was lysed with Genomic DNA Extraction kit. (iNtRON 
Biotechnology, Inc, Korea) PCR amplification was conducted with Maxime 
PCR Premix (i-Star Taq) (iNtRON Biotechnology, Inc, Korea) under the 
following conditions: 95°C for 5 minutes, followed by 25 cycles of 95°C for 35 
seconds, 58°C for 30 seconds, and 72°C for 45 seconds. PCR products were 
finished with a final extension step at 72°C for 5 minutes. For determination of 
the gender of mouse newborn, the abdominal skin was dissected after 
euthanasia. Tissue was lysed with Genomic DNA Extraction kit. (iNtRON 
Biotechnology, Inc, Korea) PCR amplification was conducted under the 
following conditions: 95°C for 4.5 minutes, followed by 33 cycles of 95°C for 
35 seconds, 58°C for 1 minute, and 72°C for 1 minute, then the PCR was 
finished with a final extension step at 72°C for 5 minutes. PCR products were 
loaded onto 1% agarose gel (USB Corporation, USA) and electrophoresed for 
20 minutes. Images were taken under UV transillumination with molecular 
image software. (Kodak) Sequences of primers were listed in Table S1. 
Primary culture of BMMCs and bone marrow MSC  
The mice were anesthetized with zoletil/xylazine (20 mg/kg and 10 mg/kg, 
respectively) mixture and were euthanized via CO2 inhalation. The bone 




(DMEM low glucose, WELGENE, Cat. LM 001-12; 10% FBS and 1% 
antibiotic-antimycotic) and was collected in a 10 ml tube. For culturing 
BMMCs, the cells were cultured with basic DMEM medium containing 
macrophage-colony stimulating factor (M-CSF, ) at 25 ng/ml. For culturing 
MSCs, the cells were cultured with the basic medium. All the cells were 
cultured in a humidified chamber at 37 °C with 5% CO2. 
TRAP staining 
The BMMCs was seeded in 12-well plate with a density of 0.1 × 106. The 
control group was cultured with basic DMEM medium and 25 ng/ml M-CSF. 
The induce group was treated with basic DMEM medium, 25 ng/ml M-CSF 
and 50 ng/ml RANKL (PEPROTECH, Cat. No. 315-11). The medium was 
changed every 2 days. After 7 days after induction, the cells were stained 
following the instruction of the TRAP staining kit (SIGMA-ALDRICH, LOT, 
SLBP7748V) 
shRNA transfection of MC3T3-E1 cell 
To diminish the transcription level of Drg2 in MC3T3-E1 cell line, shRNA 
(SANTA CRUZ BIOTECHNOLOGY, INC) was used following the 
manufacturer’s instruction. For transfection, Lipofectamine (Thermo Fisher 
Scientific) containing 1 μg DRG2 shRNA Plasmid was mixed into opti-MEM 




The shRNA plasmid transfection medium was added in each well in a 6-well 
plate. Then the cells were incubated in a standard environment (5% CO2, 37 
ºC ) for 5 hours. For selecting stably transfected cells, 10 μg/ml puromycin was 
added into the basic culture medium, i.e., alpha-MEM containing 10% FBS and 
1% antibiotic-antimycotic (Thermo Fisher Scientific). The medium was 
changed every 2-3 days. 
Inducing osteoblastic differentiation in MC3T3-E1 cells 
MC3T3-E1 cells were induced with α-MEM (containing 10% FBS and 1% 
antibiotic-antimycotic) based osteoinduction medium that contained 10-8 M 
dexamethasone, 100 μmol ascorbic acid, and 10 mM β-glycerophosphate. 
Western blot 
Cells were harvested in  RIPA buffer containing protease/phosphatase 
inhibitor (Thermo Fisher Scientific), and the protein was quantified using BCA 
assay. Primary antibodies used for immunoblotting include: beta-actin 
Rabbit mAb (Cell Signaling #8457) at a 1:2000 dilution, p38 MAPK 
Rabbit mAb (Cell Signaling, #8690) at a 1:2000 dilution, phospho-p38 
MAPK Rabbit mAb (Cell Signalling #4511) at a 1:1000 dilution,  
phospho-Smad1 Rabbit mAb  (Cell Signaling, #5753), phopho-
Smad1/5 Rabbit mAb (Cell Signaling, #9516) at a 1:1000 dilution, Smad 




Rabbit mAb  (Cell Signaling, #38454) at a 1:1000 dilution, Smad 5 
Rabbit mAb  (Cell Signaling, #12534) at a 1:1000 dilution. The 
secondary antibody used was Anti-rabbit IgG, HRP-linked Antibody  
(Cell Signaling, #7074). Chemiluminescent signals were detected with 
ECL Select western blotting detection reagent (GE Healthcare, RNP2235) 
under Fujifilm LAS 4000. 
Semiquantitative RT-PCR 
Expression level of Drg2 was monitored with semi-quantitative RT-PCR, with 
primer kit from SANTA CRUZ BIOTECHNOLOGY, INC (product number 
DRG2 (m):sc-143171-PR).  
Feeding and maintaining 
All procedures involved the use of animals were officially approved. 
(SSBMC-IACUC No. 2017-0007). Animals were kept in a specific-pathogen-
free house. They were provided with abundant food and water and with a 12:12 
dark/light cycle. Genotyping of tail tissue DNA was conducted with primers 
shown in Supplemental Table 1. These animals were maintained for more than 




Serum P1NP and CTX measurement 
Eight weeks female mice were anesthetized with zoletil/xylazine (20 mg/kg 
and 10 mg/kg, respectively) mixture. After general anesthesia, blood was 
collected via cardiac puncture from each mouse. The blood was collected into 
serum separation tube. 
Serum P1NP and CTX levels were measured with specific ELISA kits for 
mouse P1NP (MyBioSource, #X03147743) and CTX (MyBioSource, 
#32289442). Sensitivity was 0.6 ng/ml for CTX and 1.17 pg/ml for P1NP. Intra- 
and inter-assay variation coefficients were ≤ 8.0% and ≤ 12% for the CTX kit 
and < 8.0% and < 10% for the P1NP kit, respectively.  
Ovariectomy 
Eight weeks old female mice were anesthetized with intraperitoneal injection 
of 20 mg/kg Zoletil mixed with 10 mg/kg xylazine. Surgical procedures were 
performed in semi-sterile conditions. The surgical site was shaven and sterilized 
with povidone iodine solution. After a lateral incision, the ovary in the OVX 
group was exposed and removed. It was put back to the abdominal cavity in the 
sham group.[47] All procedures involving the use of animals were approved by 
the IACUC (SSBMC-IACUC No. 2017-0007). Sixteen weeks after surgery (24 
weeks of age), mice were euthanized and their spines (L1-L5) and femurs were 






Calcein labeling followed a protocol published before.[44] Eight weeks male 
mice were injected with calcein solution at 7 days and 5 days prior to their 
scarification. Their vertebrae and hind limbs were harvested and kept in 10% 
formalin for 2 days and 5 days, respectively. After removing the muscle tissue 
of each the samples, femurs and tibia were incubated in 10% KOH for 8 days 
and vertebra were incubated for 4 days in 10% KOH. Bone was processed in a 
vacuum infiltrating tissue processor and embedded in paraffin. The bone was 
then sectioned with Leica rotatory microtome at a thickness of 4 μm. Two 
sections with 40 μm to 50 μm apart were obtained from each sample. These 
sections were observed under a fluorescence inverted microscope. Their 
mineralized surface and internal distance were measured following a previously 
published method.[48] 
Statistics 
For in vivo data, each n value corresponds to a single sample. For in vitro data, 
each n value corresponds to an independent well. All data were presented as 
mean and standard deviation. Statistical analysis was performed with t-test and 
p-value (two-sided) less than 0.05 was deemed as statistically significant. All 







At the 3rd day, no significant difference was found between groups. At the 7th 
day, the cells treated with BMP-2 showed higher expression than control and 
induction group. In 10 ng/ml and 50 ng/ml groups, ErhBMP-2 groups showed 
a higher activity while CrhBMP-2 showed higher levels at the doses of 100 
ng/ml, 250 ng/ml, and 500 ng/ml. At the 14th day, both BMP-2 had similar ALP 
activities at 10 ng/ml, 50 ng/ml and 500 ng/ml doses, while CrhBMP-2 had 
higher activity at 100 ng/ml and 250 ng/ml. (Fig. 1) 
ALP staining 
No significant difference was observed between all groups on the 3rd day. At 
the 7th day, BMP-2 treated groups began to show higher expression level than 
control and induction groups, also showed a dose-dependent increase in stain 
density. In the 10 ng/ml group, ErhBMP-2 and CrhBMP-2 showed similar stain 
level, and in other groups, CrhBMP-2 had more intense color than ErhBMP-2. 
At the 14th day, all CrhBMP-2 groups showed higher ALP activity except the 
10ng/ml group. (Fig. 2) 
Calcium assay  
Accumulation of calcium was only detectable in 500ng/ml CrhBMP-2 group 




all doses except 10ng/ml. At the 14th day, except 10ng/ml, CrhBMP-2 showed 
higher calcium level than ErhBMP-2. (Fig. 3) 
Alizarin red staining 
No calcium deposit could be observed on the 7th day, and at 10th day, the 
stained calcium deposits could be observed in 250ng/ml and 500ng/ml 
CrhBMP-2 group. At the 14th day, the accumulation of mineral could be 
observed in all groups. Though no significant difference was observed, 
CrhBMP-2 groups showed slightly more intense staining compare with their 
ErhBMP-2 counterparts. (Fig. 4) 
Real-time PCR 
The expression levels of bone formation related genes were measured at 7th 
day after osteoblastic induction. The expression levels of ALP and BSP were 
higher in all CrhBMP-2 groups than ErhBMP-2 groups. The expression levels 
of OCN and OPN were higher in CrhBMP-2 at 10ng/ml, 50ng/ml, 100ng/ml 
and 250 ng/ml groups. The expression levels of Runx-2 were similar between 
ErhBMP-2 and CrhBMP-2 at doses of 250 and 500 ng/ml. In other doses, the 
CrhBMP-2 had higher levels than ErhBMP-2. (Fig. 5) 
Animal experiments 
With DBM as the carrier, ErhBMP-2 performed significantly higher 




group had 48% higher BV/TV and 38% higher coverage ratio and half of Tb.Sp 
than CrhBMP-2 group did, all with statistical significance. But the Tb.Pf in 
ErhBMP-2 group was significantly higher than that of CrhBMP-2, which 
indicated the bone in ErhBMP-2 group was less continued than the bone in 
CrhBMP-2. (Table 1) On the 8th week, the ErhBMP-2 group showed 4.26 times 
higher BV/TV, 1.86 times higher coverage ratio, 3.58 times narrower Tb.Sp and 
2.94 times more Tb.N than CrhBMP-2 group, all with statistical significance. 
(Table 1) The significantly lower SMI in ErhBMP-2 group indicated it had 
more spherical cavities in bone; and the significantly lower Tb.Pf and DA 
indicated the bone in ErhBMP-2 was more continued and isotropic than 
CrhBMP-2. 
The histomorphometric characters of new bone observed in histology sections 
were consistent with the results of micro-CT. On the 4th week, the bone volume 
in ErhBMP-2 group was significantly higher; and bridging of newly formed 
bone could only be observed in that group. Meanwhile, the newly formed bone 
in ErhBMP-2 had a cyst-like structure and more adipose tissue. On the 8th week, 
the ErhBMP-2 induced significantly more bone than CrhBMP-2 did, and the 
bone in ErhBMP-2 was more continued and isotropic than the bone in 
CrhBMP-2 group. (Fig. 6, Fig. 7) 
Characteristics of included studies and risk of bias  
A total of 6157 articles were identified. Among them, 608 were subjected to 




included in this study (Fig. 8). Among them, 34 compared the effects of 
medications with control groups. Bisphosphonates (BPs) were compared in 19 
RCTs,[49-67] calcitonin in 3 [68-70], hormone replacement therapy (HRT) in 
3,[71-73] parathyroid hormone (PTH) or teriparatide in 4,[74-77] denosumab 
in 2,[78, 79] and selective estrogen receptor modulators (SERMs) in 3.[80-82] 
Five trials compared between the effects of medications, risedronate vs. 
etidronate,[83] ibandronate vs. risedronate,[84] romosozumab vs. 
alendronate,[85] and teriparatide vs. risedronate.[86, 87] Follow-up duration in 
most trials was 2 to 3 years. Other basic characteristics of the included studies 
were summarized in Table 2.  
Approximately half of the biases were rated as unclear risk (Supplementary 
Material 2). Risk of other sources of bias was rated as high in one study because 
the criteria used in its two clinical centers were different.[53] Performance bias 
was rated as high risk in 6 trials for significantly different compliance between 
groups [58, 77, 82] and the open-label study design used in 4 trials.[52, 59, 68, 
71] 
We treated a group in which participants accepted Teriparatide 1.2 µg/week 
delivered via subcutaneous injection as a control group, following the original 
study.[76] The robustness of the results was examined using a sensitivity 
analysis. Sorensen et al. reported a 2-year extension trial [55] of a 3-year 
original trial[54]; they treated the initial time point of extension trial as the 
baseline. Therefore, we deemed the data were not duplicated and pooled them 




trial was rated as high due to the significantly imbalanced medication history 
(Supplementary Material 2).  
Comparison with control group 
Antiresorptive medications 
The result of antiresorptive medications, including BPs, HRT, SERMs, 
calcitonin, and denosumab, were pooled together to investigate the effects of 
the medications. Thirty-three studies involving 21,012 participants were 
included. The result indicated that the administration of antiresorptive 
medications could significantly reduce the risk of the secondary OVCF (RR, 
0.59; 95% CI, 0.53-0.65, p < 0.00001) (Table 3, Supplementary Material 3a). 
Bisphosphonates did not significantly increase gastrointestinal (GI) complaints 
(RR, 1.02, p = 0.45; Supplementary Material 3b). The result was treated as a 
secondary outcome because of the heterogeneity in the comparison. 
Zoledronate 
Moderate quality evidence proved that zoledronate could significantly 
decrease the risk of secondary OVCF (RR, 0.34; 95% CI, 0.17-0.69, p = 0.003; 
Fig. 9a, Table 3), without significant increase in discontinuation due to 
medication (RR, 1.99; 95% CI, 0.76-5.25, p = 0.16; Table 4, Supplementary 
Material 3c). Additionally, zoledronate could significantly decrease event ratio 
of non-vertebral fractures (RR, 0.54; 95% CI, 0.32-0.91; p = 0.02; Table 3, 





High quality evidence proved that administrating alendronate significantly 
reduced the proportion of participants who had subsequent vertebral fractures 
(RR, 0.54; 95% CI, 0.43-0.68; p < 0.0001; heterogeneity, p = 0.63, I2 = 0%; Fig. 
9b, Table 3). No significant increase in GI complaints or discontinuation was 
observed in the alendronate group (GI complaints, RR, 1.03, p = 0.55; 
Discontinuation, RR, 0.88, p = 0.46; Table 4, Supplementary Material 3e and 
3f). Alendronate had no significant effect on preventing non-vertebral fractures 
(RR, 0.81, p = 0.07; Table 3, Supplementary Material 3g). 
Risedronate 
Moderate quality evidence indicated that risedronate had a significant effect 
on preventing subsequent fractures (RR, 0.61; 95% CI, 0.51-0.73, p < 0.0001; 
Fig. 9c, Table 3). Risedronate administration did not significantly elevate GI 
complaints (RR, 1.09, p = 0.18) or discontinuation rate (RR, 0.88, p = 0.28) 
(Table 4, Supplementary Material 3h and 3i). Risedronate had a significant 
effect on preventing non-vertebral fractures (RR, 0.71, p = 0.01; Table 3, 
Supplementary Material 3j). 
Etidronate 
Moderate quality evidence showed that the administration of etidronate could 
significantly reduce the risk of new fractures (RR, 0.50; 95% CI, 0.29-0.87, p 
< 0.01; Fig. 9d, Table 3). The result consisted with that of sensitivity test, in 
which a study [61] with small sample size and big variance was excluded 




(RR, 0.57, p = 0.12) or discontinuation (RR, 0.40, p < 0.50) between 
intervention and control groups (Table 4, Supplementary Material 3l and 3m). 
Etidronate did not have a significant effect on preventing non-vertebral 
fractures (RR, 0.95, p = 0.83; Table 3, Supplementary Material 3n). 
Ibandronate 
Moderate quality evidence proved that ibandronate administrated 2.5 mg daily 
or 20 mg intermittently could significantly reduce the fracture risk (RR, 0.52; 
95% CI, 0.38-0.71, p < 0.0001; Fig. 9e, Table 3), while insufficient dosages (0.5 
mg or 1 mg per 3 months) did not (RR, 0.87; 95% CI, 0.69-1.11, p = 0.27; Fig. 
9f, Table 3). Ibandronate did not significantly raise the risk of discontinuation 
due to adverse events (sufficient dose: RR, 0.90, p = 0.45; insufficient dose: RR, 
1.27, p = 0.07) (Supplementary material 3o and 3p, Table 4). Neither sufficient 
nor insufficient dosage of ibandronate had significant effect on preventing non-
vertebral fractures (sufficient: RR, 1.10, p = 0.47; insufficient, only hip fracture: 
RR, 0.59, p = 0.19; Table 3, Supplementary Material 3q and 3r). 
Minodronate  
Low quality evidence proved minodronate had significant effect in reducing 
secondary fracture (RR, 0.44; 95% CI, 0.31-0.63; p < 0.001; Fig. 9g, Table 3). 
Minodronate did not have a significant effect on preventing non-vertebral 





Very low quality evidence indicated significantly lower risk of secondary 
fracture due to pamidronate (RR, 0.33; 95% CI, 0.13-0.84, p = 0.02; Fig. 9h, 
Table 3). Pamidronate did not have significant effect on preventing non-
vertebral fractures (RR, 0.33, p = 0.33; Table 3, Supplementary Material 3t). 
Calcitonin 
Very low-quality evidence proved calcitonin had no significant effect on 
preventing secondary fracture (RR, 1.02; 95% CI, 0.14-7.36, p = 0.98) (Table 
3).  
HRT 
Low quality evidence proved HRT had no significant effect on prevention of 
secondary vertebral or non-vertebral fracture (vertebral: RR, 0.88; p = 0.78; 
non-vertebral: RR, 0.37; p = 0.36. Table 3. Supplementary 3u). HRT did not 
significantly elevate the risk of discontinuation (RR, 0.53, 95% CI, 0.17-1.61, 
p = 0.26; Table 4, Supplementary Material 3v). 
Parathyroid (PTH) 
Moderate quality evidence proved that the administration of teriparatide 28.2 
µg/week or 56.5 µg/week, recombinant human (rh)PTH 20 µg/day or rhPTH 
40 µg/day could significantly reduce the risk of secondary fracture (Table 3). 
The synthesized RR was 0.32 (95% CI, 0.24-0.43; p < 0.0001) and the 
heterogeneity between different doses was insignificant (p = 0.62, Fig. 10a). 
The result of the sensitive analysis that excluded the trial had teriparatide 1.4 




95% CI, 0.24-0.44, p < 0.00001). The risk of discontinuation due to medication 
was significantly raised by PTH administration (RR, 1.54; 95% CI, 1.11-2.13, 
p < 0.009; Supplementary Material 3w). Forty μg/day rhPTH significantly 
elevated the risk of discontinuation, while 20 μg/day or 56.5 μg/week did not, 
but no significant heterogeneity was observed between groups. PTH had 
significant effect on preventing non-vertebral fractures (RR, 0.53; 95% CI, 
0.36-0.78; p = 0.005; Table 3, Supplementary Material 3x) 
Denosumab 
Moderate quality evidence proved that the administration of denosumab 
significantly reduced the risk of secondary fracture (RR, 0.41; 95% CI, 0.29-
0.57; p < 0.0001; Fig. 10b, Table 3). No significant increase in discontinuation 
due to medication was observed (RR, 0.75, p = 0.29; Table 4, Supplementary 
Material 3y). Denosumab did not have a significant effect on preventing non-
vertebral fractures (RR, 0.45, p = 0.06; Table 3, Supplementary Material 3z). 
SERMs 
Both raloxifene (RLX) and bazedoxifene (BZA) could significantly reduce 
risk of secondary fracture (RLX: RR, 0.58; 95% CI, 0.44-0.76, p < 0.0001; 
BZA: RR, 0.66; 95%CI, 0.53-0.82, p = 0.0002; Fig. 10c and d). Heterogeneity 
between 60 μg/day and 120 μg/day of RLX was significant and substantial (test 
for subgroup differences, p = 0.06, I2 = 72.1%; Fig. 10c). The effect of BZA 
was proved by moderate quality evidence and the effect of RLX was supported 




Comparison between interventions 
Comparison between BPs 
Moderate quality evidence proved no significant difference in the effects on 
preventing vertebral fracture between risedronate and etidronate (RR, 1.12; p 
= 0.66; Supplementary Material 4a). High-quality evidence proved no 
significant difference between ibandronate and risedronate (RR, 1.01; p = 
0.91; Supplementary Material 4b, Table 3).  
Hormone therapy vs. BPs 
Very low-quality evidence indicated no significant difference between HRT 
and etidronate (RR, 0.63; p = 0.59; Supplementary Material 4c). Moderate 
quality evidence indicated teriparatide (20 µg/week) showed a significantly 
superior effect on preventing vertebral fracture and non-vertebral fracture than 
risedronate (vertebral fracture: RR, 1.98; 95% CI, 1.44-2.7, p < 0.0001, 
Supplementary Material 4d), without significantly increasing ratio of 
discontinuation (RR, 0.75, p = 0.05; Table 4, Supplementary Material 3aa). 
No significant difference in the effects of non-vertebral fracture was observed 
(Supplementary Material 3bb). 
Monoclonal antibody medication vs. BPs 
Low-quality evidence proved the difference between the effects of 
alendronate and denosumab on preventing vertebral fracture was not 
significant (RR, 0.69; p = 0.17; Supplementary Material 4e). Moderate quality 
evidence proved romosozumab had a significantly better effect on preventing 
secondary vertebral fracture than alendronate (RR, 0.64, p = 0.001; 




Difference between the effects of alendronate and denosumab on preventing 
non-vertebral fracture was not statistically different (RR, 1.49; p = 0.46; 
Supplementary 3cc), neither was between romosozumab and alendronate (RR, 
0.74; p = 0.05; Supplementary 3dd). 
Higher DRG2 expression correlates with lower BMD 
We firstly compared the expression level of DRG2 in bone marrow stem cells 
and BMD between osteoporosis and non-osteoporosis subjects. Six 
osteoporosis subjects and seven non-osteoporosis subjects were recruited. The 
osteoporosis group had a significantly higher age, lower BMD and T-score in 
lumbar and femur and markedly higher expression level of DRG2 than the non-
osteoporosis group. (Fig. 11, Fig. 12) 
Knocking out of Drg2 affects mice postnatal bone 
formation 
To study the biological function of Drg2 in vivo, Drg2 knockout founder mice 
with C57BL/6N background was made at the Korean Research Institute of 
Bioscience and Biotechnology (KRIBB) with CRISPR/Cas9 technique.(Fig. 13) 
Three mutant founders were fabricated, since #2 founder (49 dp deletion in 
exon3) and #7 founder (31 dp deletion in exon 3) were sterile, #4 founder with 
48 dp deletion in exon 3 were crossed with C57BL/6N mice in this study.(Fig. 




knockout (KO) mice and therefore, heterozygous mice were crossed for 
homozygous mice. 
On P1, KO newborn mice had a phenotypically normal skeleton compared 
with that of WT mice.(Fig. 15) On the 4th week, body length and weight of KO 
mice were both significantly smaller than those of WT mice in both 
genders.(Fig. 16) Staining results indicated that male KO mouse had a smaller 
but phenotypically normal skeletal structure in calvaria, mandibular, forelimb, 
and hindlimb.(Fig. 17) On the 8th week, serum P1NP level was significantly 
higher in the KO group than that in WT. Serum level of CTX was lower in the 
KO group without showing statistical significance. (Fig. 18) In the trabecula of 
vertebra and femur head, KO mice showed longer mineralization surface and 
internal distance in their 8th week.(Fig. 19) 
Inhibition of DRG2 improves bone architecture and 
BMD even in ovariectomized mice 
To examine whether knocking out of DRG2 could recover bone loss caused 
by postmenopausal, we sham-operated or ovariectomized 8 weeks old female 
mice and analyzed their bone histomorphometric of the vertebra and proximal 
femur in their 24th week. In the sham-operated group, KO mice had 
significantly higher percent bone volume (BV/TV), trabecular bone number 
(Tb.N) and bone mineral density (BMD) and significantly lower trabecular 
bone thickness (Tb.Th) and trabecular bone separation (Tb.Sp). Similarly, in 




histomorphometric parameters than WT group. Additionally, no significant 
difference was observed in BV/TV or BMD between the WT-sham and KO-
OVX groups. These results indicated KO mice had more bone mass and bone 
mineral content with a relatively stronger structure in vertebra than WT mice 
did.(Fig.20-24) 
In the femur head, the significant bone architecture change and bone mass 
decrease caused by OVX were not evidently affected by knocking out of the 
gene.(Fig. 25-27) However, in the femur neck region, KO-sham mice showed 
significantly lower bone volume but significantly higher bone thickness, 
outer.Pm/inner.Pm ratio and BMD compared to WT-sham mice. The same 
phenomena were also observed in OVX mice. When the WT-sham group and 
KO-OVX group were compared, Tb.Th, and outer.Pm/inner.Pm ratio were 
comparable between the two groups. Additionally, the BMD in the KO-OVX 
group was significantly higher than that in the WT-sham group.(Fig. 28, Fig. 
29). In the proximal femur region, the BMD of KO mice was significantly 
higher than that of WT mice in both sham and OVX groups.(Fig. 30)  
Combining these results, bone mass and architecture were impaired by OVX 
in both WT and KO mice. But the bone loss was compensated, at least partially, 




Results of the GO enrichment and KEGG pathway 
analysis 
To further predict the function and mechanisms related, functional and 
pathway enrichment analyses, including GO and KEGG, were performed using 
Affymetrix® Expression Console™ Software. The top 10 significant terms in 
biological processes, molecular function, and cellular component, and the top 
20 terms in enrichment test were listed Fig. 31. 
Inhibiting the expression of DRG2 inhibits the 
osteoclastic differentiation of BMMCs and elevates 
osteoblastic differentiation of bone marrow MSCs 
The previous study presented overexpression of the DRG2 in mice elevated 
the osteoclastic differentiation of BMMCs.[40] Therefore, we evaluated 
whether the knockout of the gene could affect the osteoclastic differentiation of 
BMMCs. Consistent with the previous study, the BMMCs from Drg2 mice 
showed lower differentiation capacity than the WT mice. After treating with 
RANKL for 7 days, the WT BMMCs showed several large and multinucleated 
osteoclast indicated sufficient osteoclastic differentiation. (Fig. 32) But no large 
OCs was observed in the KO BMMCs group and the number of OCs was also 
less than that in WT group. Also, the real-time PCR (RT-PCR) results showed 
the WT group had higher transcription levels of NFATc1 and CathepsinK than 




In the osteoblastic lineage, the MSC in KO group showed obviously denser 
ALP staining than that in WT group from the 3rd day after osteoinduction. (Fig. 
34) Also, the MSC in the KO group began to show mineral deposition on the 
7th day after induction with osteoinductive medium (OM), while the WT-MSC 
showed mineral deposits from the 14th day. On both 14th and 21st day, the KO-
MSC showed obvious calcium stain than the WT-MSC.(Fig. 35) In the ALP and 
calcium assay, KO-MSC began to show significantly higher ALP activity from 
the 7th day after induction, and significantly higher calcium level from the 14th 
day after induction. (Fig. 36) The real-time PCR result indicated higher 
transcription levels of Runx2, Ocn, Col1, Bsp and Alp in KO-MSC 14 days 
after treating with OM. (Fig. 37) 
Inhibiting the expression of DRG2 elevates osteogenicity 
of MC3T3-E1 cells 
To furtherly investigate the function of Drg2 in osteoblastic differentiation, we 
inhibited the expression of Drg2 in mouse preosteoblast MC3T3-E1 cells with 
shRNA.(Fig. 38) Functionally, shRNA-Drg2 E1 cells showed denser ALP 
staining than control E1 cells after inducing with OM for 7 d, 14 d, and 21 
d.(Fig. 39). Alizarin red staining results also showed more evidently mineral 
deposit compared with control E1 cells after treatment with OM for 14 d and 
21 d. (Fig. 40). The result of ALP and calcium assay also showed higher levels 
in the shRNA-Drg2 E1 cell group than the control E1 cells when both cells 




Expression levels of osteoblast phenotypic marker genes, including bone 
sialoprotein (Bsp), collagen 1 (Col1) osteopontin (Opn) and osteocalcin (Ocn) 
were markedly elevated after induced by OM. The shRNA-Drg2 E1 cell group 
had significantly higher expression levels in Bsp, Col1, and Alp compared with 
control E1 cell group while both were treated with OM. (Fig. 42) 
Inhibition of DRG2 elevates OB differentiation via 
canonical and non-canonical BMP signaling 
To gain insight into the mechanism of Drg2 regulating osteoblast 
differentiation, we screened major transcription factors involved in osteoblast 
differentiation.[88] Among candidate transcription factors, expression levels of 
osterix (Osx), runt-related transcription factor (Runx2), distal-less homeobox 5 
(Dlx5) and special AT-rich sequence binding protein 2 (Satb2) were all higher 
in shRNA E1 cells. (Fig. 43)  
Since an increase of Runx2 expression could be caused by an activated BMP 
signaling, we furtherly investigated the changes in Smad-dependent canonical 
signaling and Smad-independent non-canonical signaling.[89, 90] Real-time 
PCR results showed that shRNA-Drg2 E1 cells already had a significant 
increase in expression of Smad1/5/8/4/6 before they were treated with OM. 
When osteoblastic differentiation was induced, shRNA-Drg2 E1 cells showed 




In non-canonical signaling, when cells were treated with basic medium, 
expression levels of p38-alpha, ERK1, and ERK2 were already elevated with 
inhibition of Drg2. After cells were treated with OM, expression levels of p38-
alpha, ERK1, and ERK2 were significantly higher in shRNA-Drg2 cells on the 
7th and the 14th day.(Fig. 45) These results indicated that Drg2 influenced 
osteoblast differentiation via canonical and non-canonical BMP pathway. 
The western blot results showed a thicker band of p-Smad1/5 in shRNA-Drg2 
E1 cells after treated with OM. The level of p-Smad1 in shRNA-Drg2 E1 cells 
was lower on the 3rd day but was higher on the 7th and 14th day after induced. 
After treated with OM, the level of p-p38 was slightly lower in shRNA-Drg2 






Osteoporosis often accompanies with iatrogenic instability and fracture 
following surgery, which remains a clinical challenge for the spine surgeon. 
Multidisciplinary approaches are encouraged and the preoperative plan is 
critical for obtaining successful fusion.[2] Since osteoporosis is caused by 
negative bone remodeling, antiresorptive and anabolic agents have been 
developed to promote bone formation. As a widely used growth factor that 
promotes osteogenesis, the effect of BMP-2 was less investigated that was 
mainly due to the lacking data of the use of BMPs in osteoporotic patients.[1] 
The theoretical advantages of using BMPs include the potential of inducing a 
rapid increase in bone strength and bone. Several preclinical studies have 
investigated the effect of BMPs in osteoporotic animal models [3] and Park et 
al. have presented early spinal fusion in the rat OVX osteoporosis model with 
BMP-2 treatment.[91] Despite the theoretical but potential benefits from BMP-
2, using rhBMP-2 comes with a high initial price that impedes its use in the 
clinic. Between the widely used rhBMP-2, ErhBMP-2 could be produced in 
large scale at a lower cost than CrhBMP-2 but had relatively less 
osteoinductivity than the latter one.[6] In the study, the authors reported more 
fatty marrow and cyst-like bone in ErhBMP-2.[6] Therefore, in the first part, of 
this series study, we compared whether using DBM as a carrier could elevate 
osteoinductivity of ErhBMP-2. [13, 92] Also, in reviewing current medications 
of osteoporosis, we noticed most of the studies focused on the primary 




reviewed the effect of the medications on preventing secondary osteoporotic 
fracture. Recently, a sclerostin inhibitor, romosozumab had been reported to 
have a significant effect on treating osteoporosis via both anti-resorptive and 
anabolic function and indicated a great potential of new medications 
development.[93] Overexpression of DRG2 was reported to increase 
osteoclastogenesis and also regulate the activity of MSC, it indicated the 
potential of DRG2 in both osteoclastogenesis and osteoblastogenesis. But the 
effect of DRG2 on osteoblastic differentiation was less investigated. Therefore, 
in the third part of this study, we investigate the effect of knocking out of DRG2 
in bone remodeling. 
The first section 
In vitro results from this study showed CrhBMP-2 had slightly higher 
osteoinductivity than ErhBMP-2 at 100 ng/ml and 200 ng/ml doses and had 
similar osteoinductivity at the dose of 500 ng/ml which was consistent with 
results from previous studies.[8, 94, 95] Additionally, the difference between 
two rhBMP-2 in ALP and Alizarin red staining was not significant. Therefore, 
the ErhBMP-2 might have slightly lower osteoinductivity that was related to its 
non-glycosylation structure, but it might be not critical for inducing bone 
formation.[8]  
Animal experiment results showed ErhBMP-2 induced significantly higher 
bone formation on both 4th week and 8th week. On the 4th week, the newly 




ratio, less surface complexity, and narrower bone separation space. On the 8th 
week, the difference became more obvious. The significant advantage of 
ErhBMP-2/DBM composites not only showed in the main parameters like 
BV/TV, Tb.N, Tb.Sp, and coverage ratio, also in Tb.Pf, BS/BV and DA. The 
parameters consistently indicated the bone in ErhBMP-2 group had 
significantly more volume, number, continuity, and isotropic, and less 
separation and surface complexity, and therefore, the data could be interpreted 
as the bone in ErhBMP-2 had the advantage in both volume and quality. 
Previous studies have shown ErhBMP-2 had compatible osteoinductivity with 
CrhBMP-2 in rat calvarial defect model,[8] dog supraalveolar peri-implant 
defect,[7] and ectopic ossification model.[6, 8, 94]  
Combined the results from cell and animal experiments, it might be 
appropriate to believe the CrhBMP-2 had advantage at lower doses in the cell 
level, but the advantage became insignificant at a dose that was sufficient for 
inducing bone formation in vivo. Also, though the bone structure is different in 
ErhBMP-2 group due to lacking heparin-binding sites, the total efficiency 
might not be affected.  
The animal experiment results indicated the newly formed bone in CrhBMP-
2 on the 8th week was lower than that on the 4th week. The time-dependent bone 
decrease was reported to be related to bone maturation or the BMP-2 carrier.[96, 
97] But in this study, it might be more attributed to the quality of the product 
we used. As the effect of rhBMP-2 was affected by various factors, the result 




appropriate to believe ErhBMP-2 have compatible osteoinductivity with 
CrhBMP-2 while loaded with DBM.  
In the histologic sections, ErhBMP-2 induced relatively more adipose tissue 
and cyst-like bone than CrhBMP-2. It was reported to be related with lack of 
heparin-binding sites in ErhBMP-2,[6] and heparin-conjugated carrier system 
was expected to reduce the fatty tissue formation and increase the density of 
newly formed bone.[9] The system reduced fatty tissue formation while loaded 
with low concentration ErhBMP-2 but did not elevate the new bone formation 
in mouse calvaria defect. 
Previous studies have reported other carriers for delivering ErhBMP-2, 
including hydroxyapatite,[99] biphasic calcium phosphate,[100] collagenated 
biphasic calcium phosphate,[101] and absorbable collagen sponge.[6-8] 
However, the efficacy of the ErhBMP and CrhBMP were only compared with 
collagen as a carrier. In this study, we proved ErhBMP-2 might have compatible 
osteoinductivity with CrhBMP-2 while carried by DBM.  
One limitation in this study is that the DBM itself might induce bone 
regeneration that could interference the comparison between two kinds of 
rhBMP-2. Also, since the DBM comes in a powder form that lacks the 
mechanical strength, it was not an ideal scaffold that could be used standalone 
for all bone defects. 
In this study, we showed ErhBMP-2 had slightly lower osteoinductivity than 




calvarial defect model. Therefore, ErhBMP-2 might have non-inferior 
osteoinductivity with CrhBMP-2 while both were carried with DBM. 
The second section 
In this study, we focused on osteoporosis patients with a history of OVCF. We 
collected related RCTs, synthesized their results, and finally estimated the 
secondary prevention effects of the medications on OVCF. We found zoledronic 
acid, alendronate, risedronate, etidronate, ibandronate, minodronate, 
pamidronate, PTH, denosumab, romosozumab, and SERMs had significant 
secondary prevention effect on OVCF. In the comparisons between the 
medications, teriparatide had a significantly superior effect to risedronate, and 
the quality of evidence was high. The effects of risedronate, ibandronate, PTH, 
and SERMs were supported by moderate quality evidence and the effects of 
alendronate, denosumab was supported by high-quality evidence.  
In the result of discontinuation due to adverse events, PTH was the only 
intervention that significantly elevated the ratio. None of the bisphosphonates 
increased the risk of GI complaints. Zoledronic acid, risedronate, and PTH had 
a significant effect on preventing non-vertebral fracture in patients with 
prevalent OVCF. 
Most of widely used BPs, include zoledronic, alendronate, risedronate, 
etidronate, and ibandronate, had a significant effect, which were supported by 
moderate quality evidences. Among the medications, risedronate and ALN are 




substantial evidence [24, 26]. Ibandronate is a nitrogen-containing BPs and IV 
injection of it allows for a dosing interval even longer than 2 months [102]. 
Zoledronic acid is another nitrogen-containing BPs that has the highest potency 
among clinical use BPs [103]. According to our result, 5mg/year iv injection of 
zoledronate could significantly reduce the risk of secondary OVCF. The 
extremely low medication frequency could be its another advantage that might 
improve patients’ compliance rate. Significantly elevated adverse events ratio 
or rare adverse events caused by BPs (e.g. osteonecrosis of the jaw or atypical 
fracture, etc.) was not reported in any trial. Insignificant difference in GI 
complaints between BPs and control group indicated properly administrated 
BPs might help avoiding the risk of GI complaints, which was consistent with 
previous studies [104]. 
PTH is a bone anabolic medication that has significant efficacy against OVCF 
[105]. Presently, moderate quality evidence proved that the injection of PTH or 
teriparatide significantly reduces the risk of secondary OVCF. Even the lowest 
dosage (28.2 µg/week) showed a significant effect. However, treatment was 
also associated with a series of adverse events that increased the risk of 
discontinuation, which was unique to the interventions included in our study. 
The most frequent adverse event was nausea. Other complaints included 
vomiting, headache, dizziness, and leg cramps.[74, 77] Nonetheless, 
teriparatide had a significantly better effect than risedronate and was the only 





SERMs included in the study were raloxifene and bazedoxifene. Both showed 
a significant effect in preventing secondary fracture. Raloxifene seemed to have 
a better effect when prescribed at a higher dosage, which was indicated by the 
significant and substantial heterogeneity between the two groups. Besides 
beneficial skeletal effects, SERMs reduce the risk of breast cancer [106]. 
However, an elevated risk of venous thromboembolic events due to raloxifene 
and bazedoxifene has been described [82]. Additionally, raloxifene 
significantly raises the risk of discontinuation.[80] Therefore, SERMs should 
be prescribed with an awareness of their risk of side effects. 
Denosumab is a RANKL inhibitor that was proved to possess a significant 
effect on preventing secondary OVCF. Side effects of it include skin rashes, 
infections, and osteonecrosis of the jaw,[105] but presently, there was no 
significant difference in adverse events compared with the control group. 
Additionally, Boonen et al. reported a significant reduction of fatal adverse 
events ratio with denosumab in patients with prevalent vertebral fracture.[79] 
One advantage of denosumab is its low dosing frequency, which might elevate 
compliance. Romosozumab is a sclerostin inhibitor that has been proved to 
have a better effect on preventing secondary OVCF than alendronate. However, 
it should be noticed that the cardiac ischemic events and cerebrovascular events 
ratio were higher in the romosozumab group. The role of sclerostin in vessels 
remains unclear, and the results from basic studies were controversial.[107-109] 




Unlike the superior effects on OVCF of most medications, only zoledronic 
acid, risedronate, and PTH had a significant effect on preventing non-vertebral 
fractures in patients with prevalent OVCF. Combined with the effects of 
medications on OVCF, the findings might indicate zoledronic acid, risedronate, 
and PTH is better options for patients with prevalent OVCF. Additionally, 
denosumab and alendronate showed marginally significant effects. The results 
might have less credibility than the main outcome because of missed 
information concerning the non-vertebral fracture status of the participants. But, 
the patients included in this study could still be considered as having a high risk 
of non-vertebral fracture because prevalent vertebral fracture and low bone 
mineral density are potential risk factors of non-vertebral fractures.[110, 111] 
Therefore, the data might be instructive for clinical usage of the medications. 
It must be noted that many phase 3 studies were excluded from this meta-
analysis because the data of patients with prevalent fractures were not reported. 
The exclusion might cause an underestimation of the effects of some newly 
developed medications like denosumab and zoledronic acid. Other limitations 
of this study include the absence of searching the gray literature, which might 
increase the risk of publication bias that might lead to an overestimation of the 
effect of newly developed medications like romosozumab and bazedoxifene. 
Additionally, our criteria for assessing the risk of bias might be too stringent, 
which might underestimate the quality of evidence. The generalizability of 
results of GI complaints was limited because most of the trials excluded patients 




Most systematic reviews and meta-analyses included osteoporosis patients, 
regardless of their fracture history that introduces indirectness in the 
results.[24-29] The results might be overestimated on patients had fracture 
history, and for optimized treatment, accurate analyses of OVCF patients are 
urged. However, only one systematic review satisfied the demand.[112] 
Compared with that, we included 12 more RCTs and a new medicine 
(romosozumab) that allowed for a more comprehensive review and allowed 
comparisons between different medications. Also, our results included vertebral 
fracture, non-vertebral fracture, GI complaints of BPs and discontinuation due 
to AEs. In the end, we evaluated the quality of evidence. The updated 
information could offer more practical evidence for clinical use. 
Our results are consistent with those from other systematic reviews about 
primary prevention of OVCF[24-26, 28, 33, 113, 114]. This could indicate that 
the medications have a consistent effect on osteoporosis patients, regardless of 
their OVCF history. Also, medications used to prevent osteoporotic fracture had 
a low risk of severe adverse events in most of the 2-3 years follow-ups. 
Therefore, the benefits of reducing the risk of fracture, disability, and mortality 
very likely outweigh the disadvantages. But, careful evaluation of risk factors 
and arrangement of drug holidays are also necessary to minimize the risk of 
adverse events.[115] 
Lack of RCTs that compared interventions of secondary prevention effect 




comparisons could be conducted through statistical analyses, high-quality 
RCTs that provide direct evidence are necessary for a solid conclusion. 
The third section 
GTP binding proteins have been found in all living organisms thus far, and 
play crucial roles in the regulation of fundamental cellular processes. Small 
monomeric GTP-binding proteins are involved in a number of essential 
processes, like signal transduction, protein synthesis and translocation, and cell 
cycle regulation.[116, 117] According to the classification of small GTP-
binding protein, a subfamily of proteins named DRG has been distinguished. 
Homologous DRG proteins have been identified in species including Xenopus, 
Drosophila, Caenorhabditis elegans, fission yeast, and halobacterium. All the 
proteins harbor the five characteristic motifs G1-G5 that are believed to interact 
with GTP. But the exact function of the DRGs is not yet known, but their 
striking conservation throughout the major kingdoms suggests an essential role 
in a fundamental pathway.[118] DRG2 regulates cell proliferation via regulates 
cell cycle proteins that involve p21 and Cdk1.[119] Also, DRG2 is a direct 
target of miR-1915-3p, and furtherly regulates cell apoptosis.[120] In 
regulating cell activity, DRG2 is associated with phosphatidylinositol 3-
phosphate–containing endosomes and depletion of DRG2 impaired the 
interaction between Rab5 and Rab-GAP5, Rab5 deactivation on endosomes and 
Tfn recycling.[121] Depletion of DRG2 significantly decreased the level of 




of membrane tubules.[123] In a previous study, overexpression of Drg2 
regulates the ratio of RANKL/OPG expressed by bone marrow stromal 
cells/osteoblast.[40] This indicates that Drg2 regulates biological function of 
the osteoblastic lineage. In this study, we identified Drg2 in osteoblast as an 
inhibitor of bone formation and a potential therapeutic target for osteoporosis. 
Osteoporosis subjects were found to have a higher expression level of DRG2 
than non-osteoporosis subjects. Drg2 knockout mice showed higher BMD and 
stronger bone architecture than WT mice under both biological and OVX 
situation. Surprisingly, inhibiting Drg2 simultaneously suppressed 
osteoclastogenesis and elevated osteoblastogenesis. The increased 
osteoblastogenesis was found to be related with both canonical and non-
canonical BMP pathways.  
BMP signaling is one of the major signal pathways that regulate osteoblastic 
differentiation, which had been reported to have crosstalk with endosome.[124, 
125] Since DRG2 localizes at the endosome where it interacts with Rab5 and 
regulates its activity,[121] it is rational to assume that Drg2 affects the activity 
of endosome and further regulates the osteogenicity via both canonical and non-
canonical BMP pathways. 
In this study, we revealed the direct effects of Drg2 on osteoblast and 
osteoclast, but it should be noticed that the genetic modified animals used were 
general knockout animal, therefore the possible changes in other organs could 
play a role in regulating the bone homeostasis.[126] Therefore, a conditional 




illuminate the specific efficacy of Drg2 in local regulation of bone 
remodeling.[127, 128] Also, the function of Drg2 in other organs should be 
further investigated before it could be used as an agent. Another point should 
be noticed is the significantly different age of subjects between non-
osteoporosis and osteoporosis groups recruited from the clinic. Though it did 
not alter the observation that Drg2 directly regulated osteogenicity of 
preosteoblast, the relation between senescence and DRG2 still should be 
investigated.  
One limitation in this study is the in-frame deletion mutation mice we used. 
Because of the sterility of the frameshift mutation mice, only the in-frame 
deletion subjects were available in this study. The sterility of the mice indicated 
a vital role of Drg2 in the reproductive system, which should be furtherly 
investigated. Also, in current stage of the study, the histomorphometric analysis 
was performed via calcein labeling and micro-CT analysis, the quantifying of 
active OB and OC in histology sections was missed due to the expenditure and 
limited number of available samples. In further studies, the histological analysis 
via various staining technology, such as Van Kossa stain, TRAP staining should 
be performed for a direct measurement of the biological activity of the OB and 
OC. Additionally, monoclonal antibody of DRG2 could be furtherly developed 
for further study of the biologic function of the gene. 
With the progressive aging of the population, osteoporosis is becoming a 
clinical and public health concern.[39] Various osteoporosis medications have 




agents.[129] Antiresorptive medications increase BMD via suppressing bone 
turnover [130, 131] but the impaired bone structure might not be restored with 
antiresorptive agents.[31] Since bone strength depends on bone microstructure 
like bone connectivity and architecture, a mere increase in BMD might not 
always reduce fracture risk.[132] Therefore, mere antiresorptive agents might 
not be an optimal strategy for treating osteoporosis. Among the anabolic 
medications, PTH has been proved to be effective monotherapy for treating 
osteoporosis, but neither teriparatide or intact PTH showed to be able to reduce 
hip fracture risk.[39] Compared with the medications, inhibiting Drg2 could 
suppress osteoclast activity and promote osteogenesis simultaneously, which 
showed a great potential of Drg2 inhibitor as an osteoporosis therapy candidate. 
This character of Drg2 finally resulted in significantly elevated BV/TV, Tb.N, 
and BMD and lower Tb.Sp in vertebrae. Additionally, among current 
medications, only potent antiresorptive medications such as alendronate, 
risedronate, zoledronate and denosumab can reduce the risk of hip fracture.[39] 
Since inhibiting Drg2 showed significantly more bone formation in both 
vertebra and femur, the Drg2 inhibitor could be a potent osteoporosis 
medication for preventing both vertebra and femur osteoporotic fracture. 
Therefore, it is rational to estimate DRG2 inhibitor could be an osteoporosis 
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Fig. 1. ALP assay result. At the 3rd day, the absorbance of CrhBMP-2 250 
ng/ml was significantly but mildly higher than that of ErhBMP-2 250 
ng/ml. At the 7th day, CrhBMP-2 showed significantly lower ALP activity 
at 10 ng/ml than ErhBMP-2 but significantly higher ALP activity at 100 
ng/ml, 250 ng/ml and 500 ng/ml. At the 14th day, CrhBMP-2 had 
significantly higher ALP activity at the dose of 100 ng/ml and 250 ng/ml. 
The experiment was biologically repeated 5 times, and the data was 






Fig. 2. ALP staining result. No significant difference was observed at the 3rd 
day. At the 7th day, BMP-2 treated groups showed a dose dependent 
increase in stain density. In the 10 ng/ml group, ErhBMP-2 and CrhBMP-
2 showed similar stain level, and in other groups, CrhBMP-2 had more 
intense color than ErhBMP-2. At the 14th day, all CrhBMP-2 groups 






Fig. 3. Calcium assay result. Accumulation of calcium was only detectable in 
500 ng/ml CrhBMP-2 group at the 7th day, and it was significantly higher 
than that of ErhBMP-2 500 ng/ml group. At the 10th day, CrhBMP-2 had 
more calcium than ErhBMP-2 at doses of 50 ng/ml, 100 ng/ml, 250 ng/ml 
and 500 ng/ml, the difference was statistically significant at the dose of 
250 ng/ml. At the 14th day, CrhBMP-2 showed higher calcium level than 
ErhBMP-2 at all doses except 10 ng/ml, and the differences were 
statistically significant at doses of 50 ng/ml, 250 ng/ml and 500 ng/ml. The 
experiment was biologically repeated 5 times, and the data was presented 






Fig. 4. Alizarin red staining result. Calcium deposit could be observed in 250 
ng/ml and 500 ng/ml CrhBMP-2 group at the 10th day. At the 14th day, 
mineral deposit could be observed in all groups, but no significant 






Fig. 5. Real-time PCR result. The expression levels of ALP were significantly 
higher in CrhBMP-2 than that in ErhBMP-2 groups at doses of 250 ng/ml 
and 500 ng/ml. The expression levels of BSP were significantly higher in 
CrhBMP-2 groups than ErhBMP-2 groups at doses of 100 ng/ml and 250 
ng/ml. The expression level of OCN was significantly higher in CrhBMP-
2 at the dose of 100ng/ml. The expression levels of OPN was significantly 
higher in the ErhBMP-2 at the dose of 500 ng/ml. The expression levels of 
RUNX2 were higher in CrhBMP-2 at all doses, but no statistical 
significance was observed. The experiment was biologically repeated 3 







Fig. 6. Micro-CT images of newly formed bone. The coverage ratio of newly 
formed bone in ErhBMP-2 group was higher than that in CrhBMP-2 group 






Fig. 7. Histology sections of newly formed bone. The bridging of new bone 
was only observed in ErhBMP-2 group. More adipose tissue and cyst-like 












Fig. 9. Forest plot of the secondary prevention effects of bisphosphonates. a, 
Zoledronate; b, Alendronate; c, Risedronate; d, Etidronate; e, Ibandronate 
(sufficient dose); f, Ibandronate (insufficient dose); g, Minodronate; h, 
Pamidronate. 
 
Fig. 10. Forest plot of the secondary prevention effects of: a, Parathyroid; b, 





Fig. 11. Age, bone mineral density (DBM) and T-score of recruited 









Fig. 13. Knocking out Drg2 with sgRNA and genomic typing of wild 






Fig. 14. Schematic diagram of experiment design of transgenic mice. 
 
Fig. 15. Alizarin red and alcian blue staining of WT and KO newborn on 
their P1. 
 
Fig. 16. Length and weight of KO and WT mice on P28. n = 12 for each 










Fig. 18. Serum level of total procollagen type 1 N-terminal propeptide 
(P1NP) and C-terminal telopeptides type 1 collagen (CTX). n = 6. 







Fig. 19. Mineralization surface and internal distance of vertebra and 
femur head ( n = 3 images/mouse). 
 
Fig. 20. Micro-CT result of vertebra. n = 25 vertebra samples in WT-
sham group, n = 30 vertebra samples each group in WT-OVX, KO-































Fig. 25. Micro-CT result of femur head. n = 11 samples in WT-sham 
group, n = 12 samples each group in WT-OVX, KO-sham and KO-
OVX group. *, p < 0.05. 
 







Fig. 27. Representative images of 3D images of femur head. 
 
 
Fig. 28. Micro-CT result of femur neck. n = 11 samples in WT-sham 
group, n = 12 samples each group in WT-OVX, KO-sham and KO-






Fig. 29. Representative images of femur neck. 
 
Fig. 30. Bone mineral density (BMD) of proximal femur. n = 11 samples in 
WT-sham group, n = 12 samples for each group (WT-OVX, or 

















Fig. 33. TRAP staining of BMMCs. After induce with RANKL for 7 
days, the BMMCs form WT mice had differentiated into 
multinucleated osteoclast. But the BMMCs from KO mice showed 
less number of differentiated osteoclast and the size of osteoclast 




Fig. 34. Real-time PCR results. The transcription levels of NFATc1 and 
CathepsinK in KO cells were lower than that in WT cells when 
both were induced with RANKL. The experiment was biologically 





Fig. 35. ALP staining of bone marrow MSC. The KO MSC showed 
obviously denser staining than its WT MSC counterparts when 
treated with basic medium or OM. 
 
Fig. 36. Calcium staining of bone marrow MSC. The KO MSC showed 
denser staining than WT MSC when both were treated with OM. 
The KO MSCs began to show mineral deposition from the 7th day. 
On 14th and 21st day the KO MSCs showed larger and denser 





Fig. 37. ALP and calcium assay. The KO group had significantly higher 
ALP activity on 7th day and 14th day compared with WT MSC 
counterpart when treated with basic medium or OM. Additionally, 
KO MSC had higher calcium level than WT MSC on both 14th day 
and 21st day after OM treatment. The experiment was biologically 
repeated 3 times. The data was presented as mean and standard 
deviation. 
 
Fig. 38. The transcription level of bone markers. The KO MSC showed 
higher transcription level of Runx2, Ocn, Col1, Bsp and Alp than 
the WT MSC when both were treated with osteoinductive medium. 
*, p < 0.05, between differentiated control and shRNA MC3T3-E1 




Fig. 39. Semi-quantitative RT-PCR results showing knocking down of 






Fig. 40. Representative images of ALP staining of control and shRNA 
treated MC3T3-E1 cells after treatment with osteoinductive 
medium (OM) on 3d, 7d,14d and 21d. The shRNA MC3T3-E1 had 
denser staining than the MC3T3-E1 cells couterparts when both 




Fig. 41. Representative images of alizarin red staining of control and 
shRNA treated MC3T3-E1 cells after basic or OM treatment. The 
shRNA MC3T3-E1 cells showed obviously denser staining than 





Fig. 42. ALP and calcium assay of control and shRNA MC3T3-E1 cells 
after basic or OM treatment. The experiment was biologically 
repeated three times, the data was presented as mean and standard 
deviation. $, p < 0.05, between undifferentiated control and shRNA 
MC3T3-E1 cells. *, p < 0.05, between differentiated control and 




Fig. 43. Real-time PCR analysis of bone markers of control and shRNA 
treated cells after basic or OM treatment for 3, 7 and 14 days. The 
experiment was biologically repeated three times, the data was 
presented as mean and standard deviation. $, p < 0.05 between 
undifferentiated control and shRNA MC3T3-E1 cells. *, p < 0.05 






Fig. 44. Real-time PCR analysis of expression levels of bone formation 
related transcription factors in control and shRNA treated MC3T3-
E1 cells with or without osteoinduction medium (OM) treatment 
for 3d, 7d and 14d. The experiment was repeated three times, the 
data was presented as mean and standard deviation. $, p < 0.05, 
between undifferentiated control and shRNA MC3T3-E1 cells. *, p 







Fig. 45. Real-time PCR analysis of expression level of Smad composites 
involved in BMP pathway. The experiment was repeated three 
times, the data was presented as mean and standard deviation. $, p 
< 0.05 between undifferentiated control and shRNA MC3T3-E1 







Fig. 46. Real-time PCR analysis of expression level of genes involved 
in non-canonical BMP pathway. The experiment was repeated 3 
times and the data was presented as mean and standard deviation. 
$, p < 0.05 between undifferentiated control and shRNA MC3T3-




Fig. 47. Representative western blots of MC3T3-E1 cells treated with 














Table 1. Micro-CT result. 
 ErhBMP-2 (13) CrhBMP-2 (13) p 
4W    
BV/TV* 46.07 (10.71) 31.12 (8.16) 0.001 
BS/BV* 22.4 (12.66) 36.32 (13.04) 0.011 
Tb.Pf* -22.76 (12.19) -35.22 (10.04) 0.009 
SMI -2.93 (0.89) -3.31 (1.22)  
Tb.Th 0.2 (0.01) 0.2 (0.01)  
Tb.N 3.18 (0.94) 2.83 (0.71)  
Tb.Sp 0.4 (0.08) 0.8 (0.12) 0 
DA 0.39 (0.15) 0.45 (0.19)  
Coverage ratio* 0.83 (0.26) 0.6 (0.14) 0.012 
8W    
BV/TV* 58.96 (12) 11.21 (4.77) 0 
BS/BV* 19.59 (14.95) 39.92 (23.37) 0.014 
Tb.Pf* -25.75 (14.5) -13.12 (5.02) 0.01 
SMI* -5.12 (2.6) -1.24 (1.44) 0 
Tb.Th 0.23 (0.04) 0.21 (0.04)  
Tb.N* 3.91 (1.82) 0.99 (0.39) 0 
Tb.Sp* 0.33 (0.11) 1.26 (0.18) 0 
DA* 0.41 (0.12) 0.59 (0.14) 0.002 
Coverage ratio* 1 (0.01) 0.35 (0.22) 0 




Table 2. Characteristics of included studies. 




















Compare with control group        
Zoledronate         
Nakamura, 2017 661 100% 74.15 G1: Zoledronic Acid 5mg/year, intravenous 
infusion; 
G2: PLC 
Both groups Both groups 2  0.6% 
Alendronate         
Black, 1996 1942 100% 71 G1: Alendronate 5 mg/d on the first 2 years, 
10mg/d on the third year 
G2: PLC 
Selectively offer Selectively offer 3  9% 
Kushida, 2004  170 100% 72 G1: Alendronate 5 mg/d 
G2: Alfacalcidol 1 µg/d 
1.5g/d  Alfacalcidol 3  30% 
Liberman, 1995 * 165 18.72% 64 G1: Alendronate 5-10 mg/d 
G2: PLC 
All groups Not reported  3 16% 
Risedronate         
Clemmesen, 1997 132 100% 68 G1: Risedronate 2.5mg/d continuously 




Not reported  3  30% 
Reginster, 2000 690 100% 71 G1: Risedronate 5 mg/d; 
G2: Risedronate 2.5 mg/d; 
G3: PLC 
All groups All groups 3  42% 
Sorensen, 2003 212 100% 72 G1: Risedronate 5 mg/d 
G2: PLC 




Fogelman, 2000 * 237 43.81% 64 G1: Risedronate 2.5 mg/d 
G2: Risedronate 5 mg/d 
G3: PLC 
All groups Not reported 2  21% 
Harris, 1999 1374 100% 69 G1: Risedronate 5 mg/d; 
G2: Risedronate 2.5 mg/d; 
G3: PLC 
All groups All groups 3  42% 
Etidronate         




G1: Etidronate 400mg/d for 14 days in a cyclic of 
90 days 
G2: Sodium fluoride 50mg/d 





Lyritis, 1997 100 100% 72 G1: Etidronate 400mg/d for 20 days in a cyclic of 
90 days 
G2: 5 days’ vitamin D+85 days calcium 
Both groups Both groups 4  26% 
Montessori, 1997 
* 
28 35% 62.5 G1: Etidronate 400mg/d for 14 days in a cyclic of 
90 days 
G2: Calcium 500mg/d 
Selectively offer Not reported 3  20% 
Shiota, 2001 * 24 60% 61.7 G1: Etidronate 200mg/d for 14 days in a cyclic of 
84 days 
G2:2 g/d calcium and 0.5 µg/d alphacalcidol for 
2 years 
Selectively offer Selectively offer 2  Not 
reporte
d 
Harris, 1993 423 100%  G1: PLC and PLC  
G2: Phosphate and PLC 
G3: PLC and Etidronate 400mg/daily for 14 in a 
cycle of 91 days 
G4: Phosphate and Etidronate 




Watts, 1990 423 100% 65 G1: PLC for 17 days in a cyclic of 91 days 
G2: Phosphonate 2g/d for 3 days in a cyclic of 91 
days 
G3: Etidronate 400mg/d for 14 days in a cyclic of 
91 days 
G4: Phosphonate 2g/d for 3 days + Etidronate 
400mg/d for next 14 days in a cyclic of 91 
days 
All groups Not reported 2 14% 
Ibandronate         
Chesnut, 2004 2929 100% 69 
 
G1: Ibandronate 2.5 mg/d, oral 
G2: Ibandronate 20mg alternate day for 12 doses 
every 3 months, oral 
G3: PLC 
All arms All arms 3 34% 
 




G1: Ibandronate 0.5mg injection, every 3 months 




All arms 3 18% 
Minodronate         




G1: Minodronate 1mg/d 
G2: PLC 
Both groups Both groups 2 
 
31% 
Pamidronate         
Reid, 1994 61 100% 66 G1: Pamidronate 150mg/d 
G2: PLC 
Both groups Not reported 2 79% 




G1: Pamidronate 150mg/d 
G2: PLC 
Both groups Both groups 3 10% 
Calcitonin         
Peichl, 1999 42 100% 62 G1: Nasal salmon calcitonin 100IU twice daily 
for 2 months with a pause of 2 months 
G2: Control group 
Both groups 
 






Hodsman, 1997 30 
 
100% 67  
 
G1: PTH sc injections 800 IU/d for 28 days in a 
cyclic of 90 days 
G2: PTH sc injections 800 IU/d for 28 days + 
salmon calcitonin 75 U/d for 42 days in a 
cyclic of 90 days 
Both groups Not prescribed 2 23% 
 
Chesnut, 2005 91 100% 67.4 G1: Calcitonin nasal spray 200 IU/d 
G2: Placebo nasal spray 
Both groups Not reported 2 78% 
Hormone replace 
therapy 
        





G2: Control group 
G3: Fluoride + Estrogen 0.625 mg/d 
G4: Estrogen 0.625 mg/d 







100% 65 G1: HRT group, Permarin 0.625mg/d + 
norgestril 150µg for 12days each month 
G2: Etidronate group, Etidronate 400mg/d for 14 
days each 12 week 
G3: Combined therapy, combination of G1 and 
G2 with same dose 
G4: control group 
All groups All groups 4 17% 
Lufkin, 1992 75 100% 65 G1: Estrogen group, Estradiol 0.1mg/d on the 
first 21 days + medroxyprogesterone acetate 
for the days 11 to 21 in a 28 days’ cycle 
G2: Placebo 
Both  Not reported 1  
Parathyroid 
hormone 
        
Neer, 2001 1637 
 
100% 71.0  
 
G1: rhPTH 20 µg/d 
G2: rhPTH 40 µg/d 
G3: PLC 









G1: Teriparatide 56.5 µg/w, sc injection 
G2: PLC, sc injection 
Both groups Both groups 
400IU/d 
1.5 26% 
Greenspan, 2001* 471 18.6% 64.4 G1: Teriparatide 100 µg/d, sc injection 
G2: PLC  
Both groups Both groups 1.5 33% 




G1: Teriparatide 28.2 µg/w, injection 
G2: Teriparatide 1.4 µg/w, injection 
Both groups Not prescribed 
 
3 17% 
Denosumab         




G1: Denosumab 60mg/6 months, sc injection 
G2: PLC 
G3: Alendronate 35mg/w 
All groups All groups 
 
3 13% 




G1: Denosumab 60mg/6 months, sc 
G2: PLC 
Both groups Both groups 3 18% 
Romozumab         
Saag, 2017 4093 100% 74.3 G1: Alendronate: 70 mg/w 
G2: Romosozumab: 210 mg/m sc injection 
Both groups Both groups 3 11% 
Raloxifene         
Ettinger, 1999 * 2304 33.74% 68 
 
G1: Raloxifene 60mg/d  
G2: Raloxifene 120mg/d 
G3: PLC 
All groups All groups 3 
 
23% 




G1: Raloxifene 60mg/d  
G2: Raloxifene 120mg/d 
G3: PLC 
All groups All groups 1 
 
9% 
Bazedoxifene         




G1: Bazedoxifene 60mg/d 
G2: Bazedoxifene 40mg/d 
G3: Bazedoxifene 20mg/d 
G4: PLC 






       
Kushida, 2004 b 547 100% 72 G1: Risedronate 2.5 mg/d  
G2: Etidronate 200 mg/d cyclically 
Both groups Not reported 2 21% 
Nakamura, 2013 1265 100% 72.7 G1: Ibandronate 0.5mg injection per month 
G2: Ibandronate 1mg iv injection per month 
G3: Risedronate 2.5 mg/d 
All arms All arms 3 10% 
Hadji, 2012 710 100% 71 G1: Risedronate: 35 mg/w 
G2: Teriparatide: 20 µg/w subcutaneous injection 
Both groups Both groups 1.5 26% 
Kendler, 2017 1360 100% 72.1 G1: Risedronate 35mg/w 
G2: Teriparatite: 20 µg/d subcutaneous injection 






Table 3. Summary of findings of osteoporotic vertebral fracture and non-vertebral fracture. 
Comparison RR (95% CI) No. of participants (studies) Quality of the evidence 
Vertebral fracture    
Antiresorptive  
medication vs. Control  
0.59 (0.53 to 0.65) 21012 (30 RCTs) - 
ZOL vs. Control 0.34 (0.17 to 0.69) 657 (1 RCT) 1 MODERATE 2, 
ALN vs. Control 0.54 (0.43 to 0.68) 2277 (3 RCTs) 3 HIGH 
RISE vs. Control 0.61 (0.51 to 0.73) 2645 (5 RCTs) 4 MODERATE 5 
Etidronate vs. Control 0.60 (0.39 to 0.92) 618 (7 RCTs) 6 MODERATE 7, 
Ibandronate (sufficient) vs. Control 0.52 (0.38 to 0.71) 2929 (1 RCT) 8 MODERATE 9, 
Ibandronate (insufficient) vs. Control 0.87 (0.69 to 1.11) 2860 (1 RCT) 10 MODERATE 11 
Minodronate vs. Control 0.44 (0.31 to 0.63) 674 (1 RCT) 12 LOW 13  
Pamidronate vs. Control 0.33 (0.13 to 0.84) 90 (1 RCT) 14 VERY LOW 15 
                                                          
1 Nakamura, 2017 
2 Study limitations: the trial included had unclear risk of performance bias.. 
3 Liberman, 1995; Black, 1996; Kushida, 2004 
4 Clemmesen, 1997; Harris, 1999; Reginster, 2000; Fogelman, 2000; Sorensen, 2003 
5 Study limitations: four trials were included, with unclear risk of selection bias, performance bias and attribution bias. 
6 Shiota, 2001; Montessori, 1997; Lyritis, 1997; Watts, 1990; Harris, 1993; Wimalawansa, 1998; Guanabens, 2000 
7 Study limitations: seven trials were included, with unclear to high risk of selection bias, attribution bias, other bias, and performance bias.  
8 Chesnut, 2004 
9 Study limitations: one trial was included, with unclear risk of performance bias and attribution bias. 
10 Recker, 2004 
11 One trial included, with unclear risk of performance bias and other bias. 
12 Matsumoto, 2009 
13 One trial was included, with unclear risk of performance bias, attribution bias and other source of bias. Imprecision: the number of events was 115 and OIS was not met. 
14 Brumsen, 2002 




Calcitonin vs. Control 1.02 (0.14 to 7.36) 157 (3 RCTs) 16 VERY LOW 17 
HRT vs. Control 0.86 (0.29 to 2.52) 147 (3 RCTs) 18 LOW 19 
PTH vs. Control 0.32 (0.24 to 0.43) 2632 (4 RCTs) 20 MODERATE 21 
Denosumab vs. Control 0.41 (0.29 to 0.57) 1654 (2 RCTs) 22 MODERATE 23 
RLX vs. Control 0.58 (0.44 to 0.76) 2447 (2 RCTs) 24 HIGH 
BZA vs. Control 0.66 (0.53 to 0.82) 3857 (1 RCT) 25 MODERATE 26 
ALN vs. Denosumab 0.69 (0.41 to 1.17) 722 (1 RCT) 27 LOW 28 
RISE vs. Etidronate 1.12 (0.69 to 1.81) 433 (1 RCT) 29 MODERATE 30 
Ibandronate vs. RISE 1.01 (0.79 to 1.31) 1228 (1 RCT)31 HIGH 
RISE vs. Teriparatide 1.98 (1.44 to 2.70) 2070 (2 RCTs) 32 HIGH 
                                                          
16 Hodsman, 1997; Peichl, 1999; Chesnut, 2005 
17 Study limitation: two trials had unclear to high risk of selection bias, performance bias, attribution bias and other bias. Imprecision (rating down two levels): 15 events and 
CIs included appreciable benefit and harm. 
18 Lufkin, 1992; Wimalawansa, 1998; Gutteridge, 2002 
19 Study limitation: two trials had unclear risk of selection bias. Two trials had unclear to high risk of performance bias. Three trials had unclear risk of attribution bias. Three 
trials had unclear risk of other bias. Imprecision (rating down two levels): 34 events and CIs included appreciable benefit and harm. 
20 Nakamura, 2012, Neer, 2001, Greenspan, 2007, Fujita, 2014  
21 One trial had unclear risk of selection bias, performance bias and attribution bias. One trial had high risk of performance bias. 
22 Boonen, 2011; Nakamura, 2014. 
23 Study limitation: two trials had unclear risk of selection bias and performance bias. One trial had had unclear risk of other bias. 
24 Ettinger, 1999, Lufkin, 1998 
25 Palacios, 2015 
26 Study limitation: one trial had high risk of performance bias and unclear risk of attribution bias and other bias. 
27 Nakamura, 2014 
28 Study limitation: one study included, with unclear risk of selection bias, performance bias, and other bias. Imprecision: the number of events was 66, and OIS was not met. 
29 Kushida, 2004 
30 Study limitation: one trial was included, with unclear risk of selection bias, attribution bias and other bias. 
31 Nakamura, 2013 




HRT vs. Etidronate 0.63 (0.12 to 3.32) 35 (1 RCT) 33 VERY LOW 34 
Non-vertebral fracture    
ZOL vs. Control 0.54 (0.32 to 0.91) 661 (1 RCT)35 - 
ALN vs. Control 0.81 (0.65 to 1.01) 2027 (1 RCT)36 - 
RISE vs. Control 0.71 (0.54 to 0.92) 2836 (4 RCTs)37 - 
Etidronate vs. Control 0.95 (0.59 to 1.53) 395 (4 RCTs)38 - 
Ibandronate (sufficient) vs. Control 1.10 (0.85 to 1.41) 2929 (1 RCT)39 - 
Ibandronate (insufficient) vs. Control 
(only Hip fracture) 
0.59 (0.26 to 1.31) 2860 (1 RCT)40 - 
Minodronate vs. Control 0.80 (0.35 to 1.84) 674 (1 RCT)41 - 
Pamidronate vs. Control 0.33 (0.04 to 3.10) 100 (1 RCT)42 - 
PTH vs. Control 0.53 (0.36 to 0.78) 2454 (3 RCTs)43 - 
Denosumab vs. Control 0.45 (0.20 to 1.03) 952 (1 RCT)44 - 
Romosozumab vs. ALN 0.74 (0.54 to 1.00) 4093 (1 RCT)45  
ALN vs. Dmab 1.49 (0.52 to 4.24) 722 (1 RCT)46 - 
                                                          
33 Wimalawansa, 1998 
34 Study limitation: one trial was included, with unclear risk of performance bias, attribution bias and other bias. Imprecision (rating down two levels): few events and CIs 
included appreciable benefit and harm. 
35 Nakamura, 2017 
36 Black, 1996 
37 Clemmesen, 1997; Harris, 1999; Reginster, 2000; Sorensen, 2003 
38 Watts, 1990; Lyritis, 1997; Montessori, 1997; Guanabens, 2000 
39 Chesnut, 2004 
40 Recker, 2004 
41 Matsumoto, 2009 
42 Brumsen, 2002 
43 Nakamura, 2012; Neer, 2001, Fujita, 2014 
44 Nakamura, 2014 
45 Saag, 2017 




RISE vs. Teriparatide 1.28 (0.94 to 1.73) 2070 (2 RCTs)47 - 
HRT vs. Etidronate 0.94 (0.06 to 13.93) 35 (1 RCT)48 - 
RR, Relative Risk; ZOL, Zoledronic acid; ALN, Alendronate; RISE, Risedronate; PTH, Pamidronate; RLX, Raloxifene; BZA, Bazedoxifene; HRT, 
Hormone replace therapy.
                                                          
47 Hadji, 2012; Kendler, 2017 




Table 4. Discontinuation due to medication. 
Comparison  No. of participants 
(studies) 
RR (95% CI) 
Zoledronate vs. Control 665 (1 RCT)1 1.99 (0.76, 5.25) 
Alendronate vs. Control 2750 (2 RCTs)2 0.88 (0.64, 1.22) 
RISE vs. Control 2707 (3 RCTs)3 0.88 (0.69, 1.12) 
Etidronate vs. Control 322 (3 RCTs)4 0.40 (0.03, 5.48) 
Ibandronate vs. Control    
2.5 mg/d & 20 mg alternatively 2929 (1 RCT)5 0.90 (0.69, 1.18) 
0.5 mg & 1 mg per 3 months 2860 (1 RCT)6 1.27 (0.97, 1.66) 
PTH vs. Control 2215 (2 RCTs)7 1.54 (1.11, 2.13) 
56.5 μg/w 578 (1 RCT)8 1.80 (1.00, 3.24) 
20 μg/d 813 (1 RCT)9 1.10 (0.62, 1.95) 
40 μg/d 824 (1 RCT)10 1.82 (1.07, 3.10) 
Dmab vs. Control 956 (1 RCT)11 0.75 (0.44, 1.27) 
HRT vs. Control 79 (2 RCTs)12 0.53 (0.17, 1.61) 
Alendronate vs. Denosumab 717 (1 RCT)13 0.79 (0.15, 4.02) 
Romosozumab vs. Alendronate 4093 (1 RCT)14 1.00 (0.58, 1.74) 
RISE vs. Teriparatide 2070 (2 RCT)15 0.75 (0.57, 1.00) 




                                                          
1 Nakamura, 2017 
2 Black, 1996; Nakamura, 2014 
3 Harris, 1999; Reginster, 2000; Sorensen, 2003 
4 Watts, 1990; Wimalawansa, 1998; Guanabens, 2000 
5 Chesnut, 2004 
6 Recker, 2004 
7 Nakamura, 2012; Neer, 2001 
8 Nakamura, 2012 
9 Neer, 2001 
10 Neer, 2001 
11 Nakamura, 2014 
12 Wimalawansa, 1998; Gutteridge, 2002 
13 Nakamura, 2014 
14 Saag, 2017 
15 Hadji, 2012; Kendler, 2017 





























































Supplementary material 1. Searching strategy. 
PubMed:  
1. randomized controlled trial[pt] 
2. controlled clinical trial[pt]  
3. randomized controlled trials[mh] 
4. random allocation[mh]  
5. double-blind method[mh] 
6. single blind method[mh]  
7. clinical trial[pt] 
8. clinical trials[mh]) 
9. clinical trial"[tw]  








18. volunteer*[tw]) NOT (animal[mh] NOT human[mh]) 
19. #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR 
#11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19  
20. Osteoporosis compression fracture  
21. osteoporotic fracture 




26. vertebrae  












36. clodronate[tiab]  
37. zoledronate[tiab] 
38. pamidronate[tiab] 
39. parathyroid hormone[tiab] 
















56. hormone replacement[tiab] 
57. hormone replacement[tw] 
58. estrogen replacement[tiab] 








64. dien estrol[tiab] 
65. dien estrol[tw] 
66. pamidronate[tiab] 
67. #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR 
#37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45 OR 
#46 OR #47 OR #48 OR #49 OR #50 OR #51 OR #52 OR #53 OR #54 OR 
#55 OR #56 OR #57 OR #58 OR #59 OR #60 OR #61 OR #62 OR #63 OR 
#64 OR #65 OR #66  




Supplementary material 2. Risk of bias table. 
Article ID Year a b c d e f g h i j k l m 
Zoledronic 
acid 
              
Nakamura 2017 + + + ? ? + ? + + + + + + 
Alendronate               
Black 1996 + + + + + + + + + + + + + 
Kushida 2004a ? ? + ? ? + ? + + + + + ? 
Liberman 1995 ? ? + - - + ? + + + + + ? 
Risedronate               
Clemmesen 1997 ? ? + ? ? + + + + ? + + - 
Fogelman 2000 ? ? + ? ? + ? + + + + + + 
Harris 1999 + + + + + + + + + ? + + + 
Reginster 2000 ? ? + ? ? + + + + + ? + ? 
Sorensen 2003 ? ? - ? ? ? ? + + + + + ? 
Etidronate               
Guanabens 2000 ? ? + ? ? ? - + + ? ? + ? 
Harris 1993 + ? + ? ? + ? + + + + + ? 
Lyritis 1997 ? ? + - - + ? + + + ? + ? 
Montenssori 1997 + ? + ? ? ? ? + + + + + ? 
Shiota 2001 ? ? + ? ? ? ? + + + ? ? ? 
Watts 2014 + ? + ? ? + ? + + + ? + ? 
Wimalawansa 1998 + ? + ? ? + ? + + + ? + ? 
Ibandronate               
Chesnut 2004 + ? + ? ? + ? + + ? + + + 
Recker 2004 + + + ? ? + + + + + + + ? 
Minodronate               
Matsumoto 2009 + + + ? ? + + + + ? + + ? 
Pamidronate               
Brumsen 2002 ? ? + + + + + + + + + + + 
Calcitonin               
Chesnut 2005 + ? + ? ? ? + + + + + + + 
Hodsman 1997 ? ? + ? ? + ? + + + ? + ? 
Peichl 1999 ? ? ? - - ? ? + + ? ? + ? 
HRT               




Lufkin 1992 ? ? + + + + ? + + + ? ? ? 
PTH               
Fujita 2014 + + + ? ? + ? + + + + + + 
Greenspan 2007 + + + ? ? + - + + ? + + + 
Nakamura 2012 + + + + + + ? + + + + + + 
Neer 2001 ? ? + ? ? + + + + + ? + + 
Denosumab               
Boonen 2011 ? ? + ? ? + ? + + + + + + 
Nakamura 2014 ? ? + ? ? + ? + + + + + ? 
SERMs               
Palacios 2015 + + + ? ? - + + + ? + + + 
Ettinger 1999 + + + + + + + + + + + + + 
Lufkin 1998 + ? + ? ? + ? + + + + + ? 
Between medication              
Ibandronate vs. Risedronate 
Nakamura 2013 + + + + + + + + + + + + + 




? ? + + + + ? + + + ? + ? 
Risedronate vs. Teriparatide 
Hadji 2012 ? ? ? + ? + ? + + + + + ? 
Kendler 2017 + + + + + + + + + + + + + 
Monoclonal antibody vs. Alendronate 
Nakamura 2014 ? ? + ? ? + ? + + + + + ? 
Saag 2017 + + + ? ? + ? + + + + + + 
Etidronate vs. HRT              
Wimalawansa 1998 + ? + ? ? + ? + + + ? + ? 
 
a, random sequence generation (selection bias) 
b, allocation concealment (selection bias) 
c, group similarity at baseline (selection bias) 
d, blinding to patients (performance bias) 
e, blinding to care providers (performance bias) 
f. influence of co-interventions (performance bias) 
g, compliance with interventions (performance bias) 
h, blinding to outcome assessors (detection bias) - Fracture 
i, timing of outcome assessments (detection bias) 
j, incompleter outcome data (attribution bias) - lost ratio 
k, incomplete outcome data (attribution bias) - ITT or modified ITT 









Reasons of being rated as unclear or high risk of bias. 




Nakamura 2017 d, Not reported; e, Not reported; g, Not reported; 
Alendronate   
Black 1996  
Kushida 2004a 
a, Not reported; b, Not reported; d, Not reported; 
e, Not reported; g, Not reported; m, Conflict of 
interest was not stated.  
Liberman 1995 
a, Not reorted; b, Not reported; d, Open label; e, 
Open label; g, Not reported; m, Conflict of 
interest was not stated. 
Risedronate   
Clemmesen 1997 
a, Not reported; b, Not reported; d, No 
description of the appreance of geltain capsules; 
e, Not reported; j: 32% i n3 years; m, the criteria 
of fracture were different in different centers. 
Fogelman 2000 
a, Not reported; b, Not reported; d, Not reported; 
e, Not reported; g, Not reported; j, 21% in 2 
years; n, no conlifct of interest stated. 
Harris 1999 j, 42% in 3 years. 
Reginster 2000 
a, Not reported; b, Not reported; d, Not reported; 
e, Not reported;, k, Not reported; m, Not 
reported. 
Sorensen 2003 
a, Not reported; b, Not reported; c, Participants 
in risedronate group already had 3 years 
risedronate; d, Not reported; e, Not reported; g, 
Not eported; m, Conflict of interest was not 
stated. 
Etidronate   
Guanabens 2000 
a, Not reported; b, Not reported; d: Not reported; 
e, Not reported; f, Participants in etidronate 
group did not receive calcium on the day they 
receive etidronate; g, Significant (p=0.01) 
difference in complaince of medications between 
groups; j, 34% in 3 years; k, no report of adverse 
events; m, no conflict of interest reported. 
Harris 1993 
b, Not reported; d, Not reported; e, Not reported; 
g, Not reported; m, Conflict of interest was not 
stated. 
Lyritis 1997 
a, Not reported; b, Not reported; d, Open label 
design; e, Open label design; g, Not reported; k, 






b, Not reported; d, Not reported; e, Not reported; 
f, Calcium intake is different between groups; g, 
Not reported; m, Not reported 
Shiota 2001 
a, Not reported; b, Not reported; d, Not reported; 
e, Not reported; f, Calcium and alfacalcidol 
supplement were different between groups; g, 
Not reported; k, Not reported;l, Safety data was 
not reported; m, Conflict of interest was not 
stated. 
Watts 2014 
b, Not reported; d, Not reported; e, Not reported; 
g, Not reported; k, Not reported; m Conflict of 
interest was not stated. 
Wimalawansa 1998 
b, Not reported; d, Not reported; e, Not reported; 
g, Not reported; k, Not reported; m, Conflict of 
interest was not stated. 
Ibandronate   
Chesnut 2004 
b, Not reported; d, Not reported; e, Not reported; 
j, 34% in 3 years. 
Recker 2004 
d, Not reported; e, Not reported; g, Not reported; 
e, Not reported; j, Not reported. 
Minodronate   
Matsumoto 2009 
d, Not reported; e, Not reported; j, 30.11% in 3 
years. 
Pamidronate   
Brumsen 2002 a, Not reported; b, Not reported. 
Calcitonin   
Chesnut 2005 b, Not reported; d, Not reported; e, Not reported. 
Hodsman 1997 
a, Not reported; b, Not reported; d, Not reported; 
e, Not reported; g, Not reported; j, 23% in 2 
years; k, Not reported; m,, Conflict of interest 
was not stated. 
Peichl 1999 
a, Not reported; b, Not reported; c, 
Concommitant medication history is different 
between participants; d, Open design; e, Open 
design; f, Vitamin D is only offered for control 
group;  
g, Not reported; j, Not reported; k, Not reported; 
m, Conflict of interest is not stated.  
HRT   
Gutteridge 2002 
b, Not reported; b, Not reported; c, Age and CaE 
at the baseline is different between groups; d, 
Open design; e, Open design;  
g, Not reported; j, 24% in 2 years; k, Not 





b, Not reported; b, Not reported; g, Not reported; 
j, Not reported; m, Conflict of interest was not 
stated. 
PTH   
Fujita 2014 
d, No specific description; e, No specific 
description; g, Not reported. 
Greenspan 2007 
c, Not reported; d, Not reported; g; Compliance 
was different among different groups.j, 32.82% 
in 18 months.  
Nakamura 2012 g, Not reported. 
Neer 2001 
a, Not reported; b, Not reported; d, Not reported; 
e, Not reporeted; j, Not reported. 
Denosumab   
Boonen 2011 
a, Not reported; b, Not reported; d, Not reported; 
e, Not reported; g, 5979 (76% received all 
injections (Cummings, 2009). 
Nakamura 2014 
a, Not reported; b, Not reported; d, Not reported; 
e, Not reported; g, Not reported; m, Sponsors 
were resposible for data collection and analysis.. 
SERMs   
Palacios 2015 
d, Not reported; e, Not reported; f, Significantly 
(p<0.01) higher proportion of Placebo-treated 
women used concomitant bone-active nonstudy 
mdications; j, 25% in extension 2; 77% in whole 
trial ( 7 years). 
Ettinger 1999  
Lufkin 1998 
b, Not reported; d, Not reported; e, Not reported; 
g, Not reported; j, Not reported; m, Conflict of 
interest is not stated. 









a, Not reported; b, Not reported; g, Not reported; 
k, 23% in 2 years; k, per protocol set was used; 





a, Not reported; b, Not reported; c, BMD of 
femoral neck is different between groups; f, Not 
reported; g, Not reported; j, 26% in 18 months; 




Kendler 2017  
Monoclonal antibody vs. Alendronate 
Nakamura 2014 
a, Not reported; b, Not reported; d, Not reported; 
e, Not reported; g, Not reported; m, Sponsors 
were resposible for data collection and analysis.. 
Saag 2017 
d, Not reported; e, Not reported; g, Not reported; 
h, Not reported. 
Etidronate vs. HRT  
Wimalawansa 1998 
b, Not reported; d, Not reported; e, Not reported; 
g, Not reported; k, Not reported; m, Conflict of 







Supplementary material 3. Forest plot of secondary outcomes.  
a. Forest plot. Effect of antiresorptive medications preventing 





b. Forest plot. GI complaints of bisphosphonates. 
 
c. Forest plot. Discontinuation due to AEs – Zoledronate 
 
d. Forest plot. Preventing non-vertebral fracture – Zoledronate  
 
e. Forest plot. GI complaints - Alendronate 
 
f. Forest plot. Discontinuation due to AEs – Alendronate 
 





h. Forest plot. GI complaints – Risedronate 
 
i. Forest plot. Discontinuation due to AEs - Risedronate 
 
j. Forest plot. Non-vertebral fracture – Risedronate 
 
k. Forest plot. Sensitivity test. Excluding a study with a small sample size and big 
variance with other studies. 
 





m. Forest plot. Discontinuation – Etidronate 
 
n. Forest plot. Non-vertebral fracture – Etidronate 
 
o. Forest plot. Discontinuation due to AEs – Ibandronate (sufficient dose) 
 
p. Forest plot. Discontinuation due to AEs – Ibandronate (insufficient dose) 
 
q. Forest plot. Non-vertebral fracture – Ibandronate (sufficient dose) 
 





s. Forest plot. Non-vertebral fracture – Minodronate  
 
t. Forest plot. Non-vertebral fracture – Pamidronate 
 
u. Forest plot. Non-vertebral fracture – HRT 
 
v. Forest plot. Discontinuation due to AEs – HRT 
 





x. Forest plot. Non-vertebral fracture – PTH 
 
y. Forest plot. Discontinuation due to AEs – Denosumab 
 
z. Forest plot. Non-vertebral fracture – Denosumab 
 





bb. Forest plot. Non-vertebral fracture – Teriparatide vs. Risedronate 
 
cc. Forest plot. Non-vertebral fracture – Alendronate vs. Denosumab 
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논 문 초 록 
DRG2 유전자의 골대사에 대한 
영향 
골다공증은 골량 감소와 골 미세구조 이상을 야기하는 질환으로 
골형성과 골흡수간 불균형에 의해 발생하며, 저손상 골절의 위험을 
증가시키는 질환이다. 새로운 골다공증 치료법을 개발하기 위하여 
다음 3 단계의 연구를 진행하였다. 골다공증 환자는 골대체제가 
필요하기 때문에 재조합 골형성단백질 제 2 형(rhBMP-2) 의 골형성 
효능 연구, 현재 사용되는 골다공증 치료제의 2 차 골절예방 효능에 
관한 메타 분석 연구와 함께, developmentally regulated GTP 
binding protein 2 (Drg2) 의 골 항상성에 미치는 영향을 
연구하였다. 첫번째 연구에서는, 대장균 유래 골형성 단백질 
제 2 형(ErhBMP-2)과 동물세포 유래 골 형성 단백질 
제 2 형(CrhBMP-2)의 골유도성을 인간 간엽줄기세포 및 랫드 
두개골 결손모델에서 비교하였고 두번째 연구에서는, 기존 골다공증 
치료제가 골다공증성 척추 및 비척추 골절을 예방하는 효과에 
대하여 메타분석을 시행하였으며 세번째 연구에서는, 골다공증이 




DRG2 의 발현을 비교하였고, Drg2 결손 마우스를 제작하여 
대조군과 골 표현형의 차이를 분석하였다. 또한 Drg2 가 
조골세포의 분화에 관여하는 기전과 신호전달 연구를 수행하였다. 
첫번째 연구에서 ErhBMP-2 가 탈회골기질을 담체로 사용할 때 
CrhBMP-2 와 유사한 골 유도능력을 가질 수도 있음을 
확인하였으며 두번째 연구에서는 골다공증 환자의 골절 병력과 
무관하게 약물치료가 지속적인 영향이 있을 수 있다는 것을 알 수 
있었습니다. 세번째 연구에서 골다공증 환자는 Drg2 mRNA 발현 
정도가 정상 대조군보다 더 높았고, Drg2 결손마우스는 
난소절제술을 시행하였을 때 골량 보호 효과가 관찰되었다. Drg2 
결손 마우스에서 얻은 골수유래 대식세포를 대조군과 비교했을 때, 
파골세포 분화력이 낮았으며 골수유래 줄기세포의 조골세포 
분화력은 높았다. 또한 마우스 MC3T3-E1 세포에서의 Drg2 
발현을 억제시키면 정식 및 비정식 BMP 경로를 통하여 조골세포의 
분화가 증가하였다. 결론적으로, 본 연구에서는 ErhBMP-2 가 
골다공증성 골절에서 동화제제로서 사용 될 수 있는 가능성과 Drg2 
유전자가 골 재형성에 있어 중요한 조절 인자임을 확인하였다. 
 
주요어: 골형성단백질 2; developmentally regulated GTP-binding 
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